The clinical role of the TME in solid cancer
The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts, and a variety of immune cells that control tumour growth and invasion. It is well established that anti-tumour immunit...
Uloženo v:
| Vydáno v: | British journal of cancer Ročník 120; číslo 1; s. 45 - 53 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
01.01.2019
Nature Publishing Group Cancer Research UK |
| Témata: | |
| ISSN: | 0007-0920, 1532-1827, 1532-1827 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts, and a variety of immune cells that control tumour growth and invasion. It is well established that anti-tumour immunity is a critical hurdle that must be overcome for tumours to initiate, grow and spread and that anti-tumour immunity can be modulated using current immunotherapies to achieve meaningful anti-tumour clinical responses. Pioneering studies in melanoma, ovarian and colorectal cancer have demonstrated that certain features of the tumour immune microenvironment (TME)—in particular, the degree of tumour infiltration by cytotoxic T cells—can predict a patient’s clinical outcome. More recently, studies in renal cell cancer have highlighted the importance of assessing the phenotype of the infiltrating T cells to predict early relapse. Furthermore, intricate interactions with non-immune cellular players such as endothelial cells and fibroblasts modulate the clinical impact of immune cells in the TME. Here, we review the critical components of the TME in solid tumours and how they shape the immune cell contexture, and we summarise numerous studies evaluating its clinical significance from a prognostic and theranostic perspective. |
|---|---|
| AbstractList | The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts, and a variety of immune cells that control tumour growth and invasion. It is well established that anti-tumour immunity is a critical hurdle that must be overcome for tumours to initiate, grow and spread and that anti-tumour immunity can be modulated using current immunotherapies to achieve meaningful anti-tumour clinical responses. Pioneering studies in melanoma, ovarian and colorectal cancer have demonstrated that certain features of the tumour immune microenvironment (TME)-in particular, the degree of tumour infiltration by cytotoxic T cells-can predict a patient's clinical outcome. More recently, studies in renal cell cancer have highlighted the importance of assessing the phenotype of the infiltrating T cells to predict early relapse. Furthermore, intricate interactions with non-immune cellular players such as endothelial cells and fibroblasts modulate the clinical impact of immune cells in the TME. Here, we review the critical components of the TME in solid tumours and how they shape the immune cell contexture, and we summarise numerous studies evaluating its clinical significance from a prognostic and theranostic perspective. The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts, and a variety of immune cells that control tumour growth and invasion. It is well established that anti-tumour immunity is a critical hurdle that must be overcome for tumours to initiate, grow and spread and that anti-tumour immunity can be modulated using current immunotherapies to achieve meaningful anti-tumour clinical responses. Pioneering studies in melanoma, ovarian and colorectal cancer have demonstrated that certain features of the tumour immune microenvironment (TME)-in particular, the degree of tumour infiltration by cytotoxic T cells-can predict a patient's clinical outcome. More recently, studies in renal cell cancer have highlighted the importance of assessing the phenotype of the infiltrating T cells to predict early relapse. Furthermore, intricate interactions with non-immune cellular players such as endothelial cells and fibroblasts modulate the clinical impact of immune cells in the TME. Here, we review the critical components of the TME in solid tumours and how they shape the immune cell contexture, and we summarise numerous studies evaluating its clinical significance from a prognostic and theranostic perspective.The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts, and a variety of immune cells that control tumour growth and invasion. It is well established that anti-tumour immunity is a critical hurdle that must be overcome for tumours to initiate, grow and spread and that anti-tumour immunity can be modulated using current immunotherapies to achieve meaningful anti-tumour clinical responses. Pioneering studies in melanoma, ovarian and colorectal cancer have demonstrated that certain features of the tumour immune microenvironment (TME)-in particular, the degree of tumour infiltration by cytotoxic T cells-can predict a patient's clinical outcome. More recently, studies in renal cell cancer have highlighted the importance of assessing the phenotype of the infiltrating T cells to predict early relapse. Furthermore, intricate interactions with non-immune cellular players such as endothelial cells and fibroblasts modulate the clinical impact of immune cells in the TME. Here, we review the critical components of the TME in solid tumours and how they shape the immune cell contexture, and we summarise numerous studies evaluating its clinical significance from a prognostic and theranostic perspective. |
| Author | Validire, Pierre Giraldo, Nicolas A. Sautès-Fridman, Catherine Ingels, Alexandre Peske, J. David Becht, Etienne Vano, Yann Petitprez, Florent Fridman, Wolf Herman Cathelineau, Xavier Sanchez-Salas, Rafael |
| Author_xml | – sequence: 1 givenname: Nicolas A. surname: Giraldo fullname: Giraldo, Nicolas A. email: ngirald1@jhmi.edu organization: Pathology Department, The Johns Hopkins University School Of Medicine – sequence: 2 givenname: Rafael surname: Sanchez-Salas fullname: Sanchez-Salas, Rafael organization: Urology Department, Institut Mutualiste Montsouris – sequence: 3 givenname: J. David surname: Peske fullname: Peske, J. David organization: Pathology Department, The Johns Hopkins University School Of Medicine – sequence: 4 givenname: Yann surname: Vano fullname: Vano, Yann organization: Oncology Department, Hopital Européen Georges Pompidou, INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team “Cancer, immune control and escape”, University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers – sequence: 5 givenname: Etienne surname: Becht fullname: Becht, Etienne organization: Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (ASTAR) – sequence: 6 givenname: Florent surname: Petitprez fullname: Petitprez, Florent organization: INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team “Cancer, immune control and escape”, University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers, Programme Cartes d’Identité des Tumeurs, Ligue Nationale contre le Cancer – sequence: 7 givenname: Pierre surname: Validire fullname: Validire, Pierre organization: Pathology Department, Institut Mutualiste Montsouris – sequence: 8 givenname: Alexandre surname: Ingels fullname: Ingels, Alexandre organization: Urology Department, Institut Mutualiste Montsouris – sequence: 9 givenname: Xavier surname: Cathelineau fullname: Cathelineau, Xavier organization: Urology Department, Institut Mutualiste Montsouris, University Paris Descartes Paris 5, Sorbonne Paris Cite – sequence: 10 givenname: Wolf Herman surname: Fridman fullname: Fridman, Wolf Herman organization: INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team “Cancer, immune control and escape”, University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers – sequence: 11 givenname: Catherine surname: Sautès-Fridman fullname: Sautès-Fridman, Catherine organization: INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team “Cancer, immune control and escape”, University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30413828$$D View this record in MEDLINE/PubMed https://hal.sorbonne-universite.fr/hal-01985551$$DView record in HAL |
| BookMark | eNp9kU9v1DAQxS1URLeFD8AFReICEgGPHf_JpVJVFYq0iMtythxn0nWVtYudrUQ_PY5SCqwEJ8szvzfvaeaEHIUYkJCXQN8D5fpDbqABWVPQNeVM1fdPyAoEZzVopo7IilKqatoyekxOcr4p35Zq9Ywcc9oA10yvyLvNFis3-uCdHasUR6ziUE2luPlyWflQ5Tj6vnI2OEzPydPBjhlfPLyn5NvHy83FVb3--unzxfm6dkLRqe47a6WjvMMGBuCKIlqhetmDFY0UCgViq5xWWlgtet22bGiZ1h06CazT_JScLXNv990Oe4dhSnY0t8nvbPphovXm707wW3Md74zkTIBsyoC3y4DtgezqfG3mGoVWCyHgDgr75sEsxe97zJPZ-exwHG3AuM-GAWeMtY1iBX19gN7EfQplFYWSgkrZ6Dn9qz_TP_r_WnoBYAFcijknHB4RoGY-rFkOW1JqMx_W3BeNOtA4P9nJx3kBfvyvki3KXFzCNabfof8t-gmHIbSU |
| CitedBy_id | crossref_primary_10_3390_cells11182793 crossref_primary_10_1002_advs_202003129 crossref_primary_10_3390_biom10060834 crossref_primary_10_3390_genes14101953 crossref_primary_10_1093_femsre_fuab017 crossref_primary_10_1007_s00428_023_03727_y crossref_primary_10_1002_cam4_5496 crossref_primary_10_1097_PAS_0000000000001323 crossref_primary_10_3390_v15010198 crossref_primary_10_3389_fcell_2022_740822 crossref_primary_10_1038_s44321_023_00022_w crossref_primary_10_1039_D5NR00964B crossref_primary_10_1016_j_smim_2020_101411 crossref_primary_10_1371_journal_pcbi_1013247 crossref_primary_10_3389_fonc_2022_884448 crossref_primary_10_1002_cjp2_271 crossref_primary_10_1016_j_cbi_2024_111038 crossref_primary_10_3390_ijms25158523 crossref_primary_10_1136_jitc_2021_003760 crossref_primary_10_1186_s12575_025_00296_z crossref_primary_10_3390_ijms23158442 crossref_primary_10_1007_s00428_024_03755_2 crossref_primary_10_1016_j_labinv_2024_102072 crossref_primary_10_1016_j_jconrel_2022_01_049 crossref_primary_10_1158_2159_8290_CD_24_0841 crossref_primary_10_3389_fonc_2022_986103 crossref_primary_10_1186_s13045_021_01085_3 crossref_primary_10_7554_eLife_95009 crossref_primary_10_3389_fbioe_2022_989881 crossref_primary_10_1007_s12672_025_02028_x crossref_primary_10_2147_IJGM_S336105 crossref_primary_10_3389_fimmu_2024_1455927 crossref_primary_10_3390_ijms241914609 crossref_primary_10_2217_fon_2022_1321 crossref_primary_10_1016_j_biomaterials_2023_122353 crossref_primary_10_1007_s12020_023_03452_1 crossref_primary_10_2147_IJN_S451151 crossref_primary_10_3390_biom15010021 crossref_primary_10_1002_cam4_4180 crossref_primary_10_1200_JCO_24_01818 crossref_primary_10_3390_ani14081224 crossref_primary_10_1186_s40246_024_00624_6 crossref_primary_10_3389_fonc_2021_769033 crossref_primary_10_1007_s12033_025_01473_x crossref_primary_10_3390_biomedicines11010125 crossref_primary_10_1016_j_omton_2025_201017 crossref_primary_10_3389_fphar_2024_1384731 crossref_primary_10_3389_fimmu_2020_582744 crossref_primary_10_1016_j_arabjc_2023_104909 crossref_primary_10_1186_s13578_020_00455_7 crossref_primary_10_1007_s00262_021_03127_8 crossref_primary_10_1186_s40164_024_00533_3 crossref_primary_10_1080_02652048_2024_2362170 crossref_primary_10_3390_cancers13112525 crossref_primary_10_2147_JHC_S394973 crossref_primary_10_3389_fmolb_2022_983840 crossref_primary_10_3390_biomedicines10061252 crossref_primary_10_1186_s12967_020_02662_9 crossref_primary_10_3390_cancers13246361 crossref_primary_10_3389_fcell_2021_754873 crossref_primary_10_1002_inmd_70054 crossref_primary_10_1002_cam4_6423 crossref_primary_10_1016_j_canlet_2025_217536 crossref_primary_10_3390_cancers12113177 crossref_primary_10_1007_s00330_020_07403_6 crossref_primary_10_3390_biomedicines9121804 crossref_primary_10_3390_cells11091454 crossref_primary_10_1007_s00262_025_04064_6 crossref_primary_10_1038_s41587_025_02629_5 crossref_primary_10_3389_fimmu_2022_950079 crossref_primary_10_1038_s41388_021_01677_w crossref_primary_10_3390_cancers13246231 crossref_primary_10_1016_j_jare_2024_10_026 crossref_primary_10_3390_cancers14092291 crossref_primary_10_1158_1535_7163_MCT_24_0756 crossref_primary_10_2147_IJGM_S341801 crossref_primary_10_3390_cancers15030597 crossref_primary_10_1186_s12964_025_02052_y crossref_primary_10_3389_fimmu_2025_1614640 crossref_primary_10_1002_ctd2_132 crossref_primary_10_1158_2326_6066_CIR_24_1144 crossref_primary_10_1016_j_neo_2024_101103 crossref_primary_10_1111_liv_15051 crossref_primary_10_3389_fimmu_2025_1595408 crossref_primary_10_3390_ijms24010155 crossref_primary_10_3390_cancers14133095 crossref_primary_10_1016_j_bioactmat_2025_01_012 crossref_primary_10_1007_s12032_025_02746_w crossref_primary_10_14423_SMJ_0000000000001347 crossref_primary_10_1016_j_ebiom_2021_103664 crossref_primary_10_1038_s41467_024_48310_4 crossref_primary_10_1093_bjd_ljad517 crossref_primary_10_3389_fimmu_2025_1519465 crossref_primary_10_1016_j_bspc_2023_105544 crossref_primary_10_3389_fendo_2020_608422 crossref_primary_10_3389_fonc_2022_781233 crossref_primary_10_1007_s12672_023_00738_8 crossref_primary_10_1186_s12885_022_09328_3 crossref_primary_10_3389_fcell_2023_1166916 crossref_primary_10_3390_genes15070961 crossref_primary_10_3390_cells10051208 crossref_primary_10_3389_fimmu_2025_1506278 crossref_primary_10_3389_fimmu_2023_1298891 crossref_primary_10_1186_s12943_023_01860_5 crossref_primary_10_1016_j_heliyon_2023_e15421 crossref_primary_10_1016_j_carbpol_2024_122253 crossref_primary_10_3390_ijms21228676 crossref_primary_10_3390_ijms26104559 crossref_primary_10_1097_CJI_0000000000000535 crossref_primary_10_1016_j_trecan_2025_06_003 crossref_primary_10_3389_fonc_2021_671629 crossref_primary_10_1111_bju_16496 crossref_primary_10_1038_s41467_024_52980_5 crossref_primary_10_1016_j_ymthe_2024_03_023 crossref_primary_10_3390_ijms24065715 crossref_primary_10_3389_fonc_2023_1145817 crossref_primary_10_3389_fimmu_2024_1374943 crossref_primary_10_3390_cancers14092266 crossref_primary_10_3389_fmolb_2024_1452290 crossref_primary_10_4251_wjgo_v17_i5_106103 crossref_primary_10_3389_fimmu_2022_956984 crossref_primary_10_1038_s41417_024_00765_9 crossref_primary_10_1088_1402_4896_adf7e4 crossref_primary_10_1002_ijc_33849 crossref_primary_10_1038_s41467_025_56275_1 crossref_primary_10_1016_j_cpt_2025_05_002 crossref_primary_10_3390_cimb47050321 crossref_primary_10_1002_ctm2_1453 crossref_primary_10_1016_j_matbio_2023_04_002 crossref_primary_10_1111_jcmm_15751 crossref_primary_10_2217_epi_2020_0046 crossref_primary_10_15446_revfacmed_v71n3_105765 crossref_primary_10_1097_PAS_0000000000002137 crossref_primary_10_1007_s00262_025_04047_7 crossref_primary_10_1038_s41389_022_00420_8 crossref_primary_10_1016_j_critrevonc_2025_104844 crossref_primary_10_3390_cells13050451 crossref_primary_10_1038_s41598_023_31426_w crossref_primary_10_1186_s12967_025_06831_6 crossref_primary_10_1002_jum_16086 crossref_primary_10_1007_s12672_023_00742_y crossref_primary_10_1016_j_jtho_2025_02_001 crossref_primary_10_1186_s12967_022_03666_3 crossref_primary_10_1007_s12032_020_01417_2 crossref_primary_10_1007_s12032_025_02860_9 crossref_primary_10_3389_fimmu_2022_1035997 crossref_primary_10_3390_cancers17010022 crossref_primary_10_3389_fgene_2021_763561 crossref_primary_10_1016_j_euros_2021_05_002 crossref_primary_10_1186_s40478_021_01273_9 crossref_primary_10_3390_ijms26115394 crossref_primary_10_1007_s00432_020_03317_4 crossref_primary_10_3390_biology14081035 crossref_primary_10_3390_biomedicines12102381 crossref_primary_10_1080_08916934_2020_1836487 crossref_primary_10_3389_fonc_2023_1152681 crossref_primary_10_3390_cancers15041282 crossref_primary_10_1007_s00066_020_01584_1 crossref_primary_10_1007_s40778_022_00215_y crossref_primary_10_1186_s12943_022_01558_0 crossref_primary_10_3390_cancers15010191 crossref_primary_10_1186_s12943_024_02209_2 crossref_primary_10_1186_s13045_024_01634_6 crossref_primary_10_1016_j_surg_2023_04_030 crossref_primary_10_3389_fimmu_2022_977338 crossref_primary_10_1002_adfm_202503391 crossref_primary_10_1007_s00210_025_04055_5 crossref_primary_10_1186_s12876_022_02621_2 crossref_primary_10_3389_fimmu_2024_1352615 crossref_primary_10_1038_s41416_020_0780_3 crossref_primary_10_1038_s41587_023_01796_7 crossref_primary_10_1158_1078_0432_CCR_22_3743 crossref_primary_10_1016_j_biopha_2024_116317 crossref_primary_10_1007_s12672_025_02408_3 crossref_primary_10_1016_j_dmpk_2024_101003 crossref_primary_10_1136_jitc_2023_007187 crossref_primary_10_1002_smll_202207252 crossref_primary_10_3390_biology13110860 crossref_primary_10_1007_s11010_025_05245_8 crossref_primary_10_3390_biomedicines12030591 crossref_primary_10_3390_ijms241814063 crossref_primary_10_1016_j_immuni_2019_12_010 crossref_primary_10_1155_2023_3754094 crossref_primary_10_3389_fphar_2024_1442888 crossref_primary_10_3389_fphar_2025_1568664 crossref_primary_10_1016_j_oraloncology_2020_104799 crossref_primary_10_3389_fcell_2021_659080 crossref_primary_10_3389_fmolb_2023_1220193 crossref_primary_10_1016_j_biotechadv_2022_107917 crossref_primary_10_1038_s41416_023_02432_6 crossref_primary_10_3390_cancers17050817 crossref_primary_10_1016_j_semcancer_2022_04_003 crossref_primary_10_1186_s12865_023_00553_4 crossref_primary_10_1016_j_addr_2021_05_001 crossref_primary_10_1038_s41598_025_09644_1 crossref_primary_10_1038_s41571_025_01061_7 crossref_primary_10_1007_s00251_020_01189_z crossref_primary_10_3389_fgene_2023_1165648 crossref_primary_10_1158_0008_5472_CAN_23_0379 crossref_primary_10_1186_s12943_023_01865_0 crossref_primary_10_1631_jzus_B2200174 crossref_primary_10_3389_fimmu_2022_859177 crossref_primary_10_1016_j_humpath_2023_03_010 crossref_primary_10_1038_s41416_022_01936_x crossref_primary_10_1007_s12032_025_02675_8 crossref_primary_10_1111_jcmm_15687 crossref_primary_10_1155_2022_3129765 crossref_primary_10_3390_ijms26167901 crossref_primary_10_3389_fonc_2020_622251 crossref_primary_10_4251_wjgo_v15_i2_225 crossref_primary_10_1002_cbin_12004 crossref_primary_10_1002_smll_202305708 crossref_primary_10_1096_fj_202200684RR crossref_primary_10_1016_j_cellsig_2023_111016 crossref_primary_10_1136_jitc_2022_006092 crossref_primary_10_1016_j_bbadis_2025_167676 crossref_primary_10_1016_j_modpat_2023_100208 crossref_primary_10_1186_s13045_021_01034_0 crossref_primary_10_3390_cancers16020295 crossref_primary_10_2147_JHC_S410756 crossref_primary_10_1186_s13045_020_00988_x crossref_primary_10_1002_cam4_3454 crossref_primary_10_1002_adhm_202303658 crossref_primary_10_1002_adma_202310673 crossref_primary_10_1007_s00428_020_02930_5 crossref_primary_10_3389_fmed_2023_1152547 crossref_primary_10_3390_cancers16010128 crossref_primary_10_3390_biomedicines13051173 crossref_primary_10_3389_fonc_2023_1170264 crossref_primary_10_3389_fonc_2022_1019111 crossref_primary_10_1007_s10565_023_09830_9 crossref_primary_10_1007_s13402_023_00790_0 crossref_primary_10_1186_s12885_021_08790_9 crossref_primary_10_1111_jcmm_17960 crossref_primary_10_1016_j_heliyon_2024_e35727 crossref_primary_10_2147_CMAR_S260915 crossref_primary_10_1007_s11684_023_1048_0 crossref_primary_10_1016_j_bbrc_2020_11_002 crossref_primary_10_3389_fmolb_2024_1340024 crossref_primary_10_1016_j_pharmthera_2022_108200 crossref_primary_10_1016_j_cellsig_2025_111874 crossref_primary_10_3390_vetsci5040100 crossref_primary_10_1063_5_0108792 crossref_primary_10_3390_cancers15010019 crossref_primary_10_3389_fonc_2021_788365 crossref_primary_10_3390_antib9040065 crossref_primary_10_1186_s40580_024_00456_z crossref_primary_10_3389_fimmu_2025_1586790 crossref_primary_10_1111_imcb_12826 crossref_primary_10_1186_s12943_021_01428_1 crossref_primary_10_2217_fon_2023_0658 crossref_primary_10_1007_s12026_023_09440_x crossref_primary_10_3389_fonc_2022_844666 crossref_primary_10_1002_mco2_100 crossref_primary_10_1111_jcmm_70080 crossref_primary_10_1016_j_it_2020_04_004 crossref_primary_10_3389_fonc_2023_1069696 crossref_primary_10_3389_fonc_2022_879405 crossref_primary_10_3389_fgene_2023_1222064 crossref_primary_10_3390_cells12242801 crossref_primary_10_1186_s12885_022_09713_y crossref_primary_10_1016_j_copbio_2023_103020 crossref_primary_10_3390_ijms24032320 crossref_primary_10_3390_ijms22094859 crossref_primary_10_1038_s41435_024_00274_7 crossref_primary_10_1016_j_addr_2023_115083 crossref_primary_10_1002_adtp_201900136 crossref_primary_10_3390_cancers14194866 crossref_primary_10_1007_s43188_024_00232_5 crossref_primary_10_3390_jcm9092967 crossref_primary_10_1038_s41420_025_02363_6 crossref_primary_10_3390_ph18071047 crossref_primary_10_1016_j_jconrel_2025_01_001 crossref_primary_10_3389_fphar_2025_1528671 crossref_primary_10_3390_jpm12040534 crossref_primary_10_1093_jjco_hyad134 crossref_primary_10_1186_s13578_023_01153_w crossref_primary_10_3389_fmed_2022_966458 crossref_primary_10_3390_cells13161334 crossref_primary_10_1038_s41598_020_62986_w crossref_primary_10_1186_s13046_025_03377_9 crossref_primary_10_3390_cancers12071722 crossref_primary_10_1038_s41416_022_02049_1 crossref_primary_10_1080_2162402X_2024_2371563 crossref_primary_10_3390_app112210787 crossref_primary_10_3390_cancers15245841 crossref_primary_10_1016_j_smim_2023_101840 crossref_primary_10_1016_j_bmc_2023_117490 crossref_primary_10_1016_j_vetimm_2019_109891 crossref_primary_10_3390_gels9060482 crossref_primary_10_3389_fimmu_2022_907182 crossref_primary_10_1016_j_jvir_2024_03_012 crossref_primary_10_3389_froh_2024_1390081 crossref_primary_10_3389_fonc_2024_1349308 crossref_primary_10_1186_s12967_023_04806_z crossref_primary_10_3390_cancers14143335 crossref_primary_10_1016_j_bbcan_2022_188805 crossref_primary_10_2217_nnm_2021_0094 crossref_primary_10_1038_s41435_022_00184_6 crossref_primary_10_1016_j_intimp_2025_114105 crossref_primary_10_1016_j_jdin_2023_12_003 crossref_primary_10_1016_j_heliyon_2024_e29326 crossref_primary_10_3390_cells9030615 crossref_primary_10_1007_s00345_020_03303_y crossref_primary_10_1016_j_dib_2025_111817 crossref_primary_10_1016_j_heliyon_2024_e32744 crossref_primary_10_1016_j_jncc_2025_03_002 crossref_primary_10_1155_2022_3035073 crossref_primary_10_1007_s12672_024_01238_z crossref_primary_10_3390_cancers15061642 crossref_primary_10_1016_j_ebiom_2022_104010 crossref_primary_10_1073_pnas_2407096121 crossref_primary_10_3389_fimmu_2025_1548234 crossref_primary_10_2147_JIR_S398284 crossref_primary_10_1002_adhm_202200690 crossref_primary_10_1007_s00262_025_03960_1 crossref_primary_10_1007_s13233_025_00442_2 crossref_primary_10_1038_s41597_025_04489_9 crossref_primary_10_1038_s41467_023_43290_3 crossref_primary_10_1186_s12951_023_02021_y crossref_primary_10_1080_14728222_2021_2011859 crossref_primary_10_3390_ijms25073779 crossref_primary_10_3389_fonc_2023_1058337 crossref_primary_10_1016_j_heliyon_2024_e30337 crossref_primary_10_3390_biomedicines9111566 crossref_primary_10_1002_adma_202209529 crossref_primary_10_2217_imt_2020_0283 crossref_primary_10_3390_gels11070562 crossref_primary_10_3389_fimmu_2024_1375013 crossref_primary_10_3390_biomedicines10081784 crossref_primary_10_1016_j_intimp_2023_110601 crossref_primary_10_3390_ijms20174320 crossref_primary_10_3802_jgo_2025_36_e114 crossref_primary_10_1038_s41598_022_12531_8 crossref_primary_10_3389_fvets_2021_771737 crossref_primary_10_3389_fonc_2024_1429330 crossref_primary_10_1089_cell_2022_0047 crossref_primary_10_1371_journal_pone_0284282 crossref_primary_10_1017_erm_2024_9 crossref_primary_10_1016_j_biomaterials_2021_121012 crossref_primary_10_1158_2159_8290_CD_23_1422 crossref_primary_10_3390_ijms25084335 crossref_primary_10_1038_s41598_024_84290_7 crossref_primary_10_3390_ijms26062795 crossref_primary_10_5306_wjco_v13_i8_663 crossref_primary_10_1186_s12885_023_11028_5 crossref_primary_10_3390_cancers14225663 crossref_primary_10_3389_fimmu_2024_1344637 crossref_primary_10_1371_journal_pone_0261175 crossref_primary_10_3389_fonc_2021_726701 crossref_primary_10_3390_ijms25010359 crossref_primary_10_1007_s00418_022_02136_7 crossref_primary_10_3389_fonc_2021_645912 crossref_primary_10_1111_imr_13286 crossref_primary_10_1038_s41392_020_00359_5 crossref_primary_10_1186_s12967_025_06839_y crossref_primary_10_1038_s44319_024_00365_6 crossref_primary_10_3390_biom12060784 crossref_primary_10_3389_fonc_2021_616629 crossref_primary_10_1016_j_csbj_2023_08_015 crossref_primary_10_1007_s00262_024_03923_y crossref_primary_10_1016_j_annonc_2021_08_2153 crossref_primary_10_1080_14728222_2023_2259096 crossref_primary_10_3390_cancers13215383 crossref_primary_10_3390_cells12060840 crossref_primary_10_1016_j_molmed_2020_09_005 crossref_primary_10_1097_MD_0000000000024903 crossref_primary_10_1016_j_heliyon_2024_e39861 crossref_primary_10_3389_fonc_2022_1014280 crossref_primary_10_3390_cancers13061374 crossref_primary_10_1002_ctd2_90 crossref_primary_10_1038_s41416_018_0330_4 crossref_primary_10_3892_ijo_2025_5774 crossref_primary_10_3389_fimmu_2022_959114 crossref_primary_10_1038_s41419_022_05129_5 crossref_primary_10_1186_s13058_021_01476_x crossref_primary_10_1038_s41598_022_10182_3 crossref_primary_10_1186_s13046_020_01570_6 crossref_primary_10_3389_fonc_2022_881207 crossref_primary_10_1038_s41388_024_03057_6 crossref_primary_10_3390_cancers14061578 crossref_primary_10_1038_s41467_023_44309_5 crossref_primary_10_1038_s41419_023_06021_6 crossref_primary_10_1038_s41467_023_36769_6 crossref_primary_10_1007_s11864_024_01245_w crossref_primary_10_1002_jcp_30643 crossref_primary_10_1002_ctm2_70012 crossref_primary_10_1007_s12033_024_01195_6 crossref_primary_10_3389_fimmu_2024_1341390 crossref_primary_10_3390_jpm14010030 crossref_primary_10_3389_fonc_2023_1259034 crossref_primary_10_1186_s12885_024_11878_7 crossref_primary_10_1128_spectrum_04104_23 crossref_primary_10_1177_17588359221077972 crossref_primary_10_1186_s13578_024_01283_9 crossref_primary_10_1016_j_heliyon_2024_e36446 crossref_primary_10_3390_immuno1020007 crossref_primary_10_1038_s41467_021_21795_z crossref_primary_10_1158_2159_8290_CD_23_0010 crossref_primary_10_1186_s12935_024_03436_9 crossref_primary_10_1016_j_isci_2024_109277 crossref_primary_10_1007_s00262_020_02616_6 crossref_primary_10_1097_CEJ_0000000000000804 crossref_primary_10_1038_s41598_023_40980_2 crossref_primary_10_1007_s11010_024_05119_5 crossref_primary_10_3389_fonc_2022_983254 crossref_primary_10_3390_cancers11111694 crossref_primary_10_1245_s10434_025_17765_0 crossref_primary_10_3390_ijms25137314 crossref_primary_10_1007_s12672_024_01156_0 crossref_primary_10_1016_j_biopha_2025_118471 crossref_primary_10_1016_j_actbio_2021_03_076 crossref_primary_10_1186_s12935_021_02297_w crossref_primary_10_3390_pharmaceutics14112388 crossref_primary_10_1016_j_biopha_2022_113370 crossref_primary_10_1186_s12885_023_11289_0 crossref_primary_10_3389_fimmu_2024_1372837 crossref_primary_10_3390_ijms26073234 crossref_primary_10_1245_s10434_023_14694_8 crossref_primary_10_3389_fcell_2022_842898 crossref_primary_10_3390_cancers14174192 crossref_primary_10_1186_s12935_022_02456_7 crossref_primary_10_3389_fgene_2022_858466 crossref_primary_10_1016_j_cej_2025_166215 crossref_primary_10_1097_CJI_0000000000000477 crossref_primary_10_1039_D1BM01802G crossref_primary_10_1016_j_bbrc_2024_149820 crossref_primary_10_1016_j_compbiomed_2025_110938 crossref_primary_10_1021_jacs_4c13241 crossref_primary_10_3390_ijms26094292 crossref_primary_10_3389_fmolb_2020_00148 crossref_primary_10_1016_j_intimp_2020_106795 crossref_primary_10_3389_fimmu_2022_975787 crossref_primary_10_1016_j_biomaterials_2022_121947 crossref_primary_10_3389_fonc_2020_545385 crossref_primary_10_1016_j_prp_2024_155775 crossref_primary_10_1080_17460441_2023_2216016 crossref_primary_10_1002_path_6238 crossref_primary_10_1007_s00251_021_01223_8 crossref_primary_10_1016_j_taap_2024_116975 crossref_primary_10_1038_s44276_025_00146_1 crossref_primary_10_1038_s41573_021_00195_4 crossref_primary_10_1016_j_euo_2025_03_016 crossref_primary_10_1016_j_ejca_2021_05_035 crossref_primary_10_1080_14737159_2025_2544233 crossref_primary_10_1002_jcp_29969 crossref_primary_10_3390_cancers14102408 crossref_primary_10_1016_j_intimp_2023_110213 crossref_primary_10_1016_j_bioactmat_2023_10_017 crossref_primary_10_1016_j_semcancer_2022_09_005 crossref_primary_10_1002_hed_27945 crossref_primary_10_1136_jitc_2020_000529 crossref_primary_10_1186_s12943_020_01260_z crossref_primary_10_1186_s12957_022_02538_w crossref_primary_10_3389_fimmu_2024_1371831 crossref_primary_10_1016_j_cellsig_2022_110567 crossref_primary_10_1002_cmdc_202300647 |
| Cites_doi | 10.1038/nature12213 10.1126/science.aad1329 10.1016/j.cell.2017.04.004 10.1016/j.cell.2014.03.011 10.1038/nrc.2016.154 10.1016/j.ccr.2012.04.024 10.1038/nrc.2016.36 10.18632/oncotarget.23742 10.1038/bjc.2013.493 10.1016/S0140-6736(15)01281-7 10.1016/j.immuni.2016.02.025 10.1016/S1470-2045(15)70076-8 10.1053/j.gastro.2013.07.025 10.1126/science.aan6733 10.1084/jem.20151159 10.1038/35025220 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5 10.1200/JCO.2011.37.8539 10.1038/nature13904 10.1056/NEJMoa1504030 10.1200/JCO.2016.34.15_suppl.3500 10.1158/2159-8290.CD-15-1545 10.1038/nrclinonc.2017.101 10.1038/nature14011 10.1056/NEJMoa1504627 10.1038/nature12721 10.1158/0008-5472.CAN-11-0952 10.1038/bjc.2013.634 10.1038/nrc.2015.5 10.1200/JCO.2016.66.9929 10.1038/nature12726 10.1164/rccm.200806-951OC 10.1126/science.aan4236 10.1056/NEJMoa1412082 10.1038/nrc2444 10.1158/1078-0432.CCR-15-2879 10.4049/jimmunol.174.8.4670 10.1158/1078-0432.CCR-15-0244 10.1158/1078-0432.CCR-16-2848 10.1053/j.gastro.2008.07.016 10.1016/bs.ai.2015.12.002 10.1002/cncr.23712 10.1038/nm1699 10.1164/rccm.201309-1611OC 10.1002/jso.23095 10.1038/nature06868 10.1016/j.ccell.2014.10.006 10.1016/j.it.2014.09.006 10.1158/2159-8290.CD-14-0863 10.1016/S0140-6736(16)00587-0 10.1016/S1470-2045(15)70054-9 10.1038/ncomms8114 10.1056/NEJMoa1200690 10.1016/S1470-2045(17)30240-1 10.1172/JCI44952 10.1073/pnas.1609376113 10.1126/science.1235122 10.1158/0008-5472.CAN-08-2281 10.4049/jimmunol.178.9.5552 10.1038/nature18848 10.1016/j.ccr.2012.02.007 10.1038/nature12477 10.1038/nri.2017.145 10.1126/science.aaf1490 10.1200/JCO.2012.43.4589 10.1038/sj.bjc.6602934 10.1001/jama.2017.14155 10.1200/JCO.2016.68.1478 10.1056/NEJMoa1500596 10.1038/nrc1252 10.1200/jco.2015.33.18_suppl.lba100 10.1038/nature14404 10.1038/modpathol.2017.156 10.1016/j.jhep.2017.05.014 10.1007/s10549-013-2752-2 10.1038/sj.leu.2403240 10.1186/s13059-016-1070-5 10.1126/science.aaa4971 10.1007/s00428-015-1787-7 10.1093/jnci/81.24.1893 10.1200/JCO.2014.59.0703 10.1158/2326-6066.CIR-17-0190 10.1007/s10549-010-1154-y 10.1172/JCI67428 10.1016/j.immuni.2017.11.016 10.1200/JCO.2014.58.3708 10.1200/JCO.2015.63.7421 10.18632/oncotarget.14374 10.1126/scitranslmed.3006438 10.1056/NEJMoa1507643 10.1172/JCI32205 10.1038/nature13954 10.1126/science.1241165 10.1038/nrclinonc.2016.217 10.1158/0008-5472.CAN-11-3218 10.1016/j.athoracsur.2008.10.067 10.1126/science.1240527 10.1200/JCO.2005.01.4910 10.1038/nature10434 10.1007/s00262-012-1231-7 10.1016/j.coi.2014.01.001 10.1016/j.cell.2016.02.065 10.1016/j.coi.2018.03.005 10.1016/S0140-6736(16)32455-2 10.1038/modpathol.3800517 10.1158/2159-8290.CD-17-1327 10.1016/j.cell.2015.08.016 10.1126/science.aan3706 10.1001/jamaoncol.2017.2411 10.1016/j.canlet.2013.01.036 10.1111/imr.12405 10.1016/S1470-2045(16)00175-3 10.1038/nature10138 10.1126/science.aao3290 10.1016/j.jss.2009.08.029 10.1038/nature07450 10.1007/s12094-014-1235-1 10.1038/nm934 10.1158/2159-8274.CD-10-0028 10.1158/0008-5472.CAN-14-1491 10.1080/2162402X.2015.1049804 10.1016/S1470-2045(16)30496-X 10.1200/JCO.2016.67.9761 10.1073/pnas.1424927112 10.1038/nrc.2016.52 10.1038/nrc3245 10.1146/annurev.immunol.25.022106.141623 10.1200/JCO.2013.51.3002 10.1158/0008-5472.CAN-13-1342 10.1126/science.aaa1348 10.1126/science.1240537 10.1016/j.celrep.2016.03.075 10.1038/nm.3337 10.1016/j.cell.2017.11.013 10.1371/journal.pone.0095475 10.1073/pnas.1013805107 10.1038/ncomms1239 10.1056/NEJMoa1709684 10.1016/j.cell.2013.10.015 10.1136/jclinpath-2011-200355 10.1038/nature12331 10.1200/JCO.2016.71.6795 10.1016/S0140-6736(16)00561-4 10.1073/pnas.1320753111 10.1002/eji.200323057 10.1158/1078-0432.CCR-14-2926 10.1159/000438523 10.1183/09031936.00065708 10.1056/NEJMoa1501824 10.1016/j.coi.2015.11.009 |
| ContentType | Journal Article |
| Copyright | Cancer Research UK 2018 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: Cancer Research UK 2018 – notice: 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7U9 7X7 7XB 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AN0 AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 1XC VOOES 5PM |
| DOI | 10.1038/s41416-018-0327-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Database ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest Central Student |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-1827 |
| EndPage | 53 |
| ExternalDocumentID | PMC6325164 oai:HAL:hal-01985551v1 30413828 10_1038_s41416_018_0327_z |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- -Q- 0R~ 23N 36B 39C 4.4 406 53G 5GY 5RE 6J9 70F 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 AACDK AANZL AASML AATNV AAWTL AAYZH AAZLF ABAKF ABLJU ABOCM ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACPRK ACRQY ACZOJ ADBBV ADFRT ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMYLF AN0 AOIJS ASPBG AVWKF AXYYD AZFZN BAWUL BBNVY BENPR BHPHI BKEYQ BKKNO BNQBC BPHCQ BVXVI C6C CCPQU CS3 DIK DNIVK DPUIP DU5 E3Z EAP EBLON EBS EE. EIOEI EJD EMB ESX EX3 F5P FDQFY FEDTE FERAY FIGPU FIZPM FRJ FSGXE FYUFA GX1 HCIFZ HMCUK HVGLF HYE HZ~ IH2 IWAJR JSO JZLTJ KQ8 M1P M7P NAO NAPCQ NQJWS O9- OK1 P2P PQQKQ PROAC PSQYO Q2X RNT RNTTT ROL RPM SNX SNYQT SOHCF SOJ SRMVM SWTZT TAOOD TBHMF TDRGL TR2 UKHRP W2D WH7 WOW ~02 AAFWJ AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFHIU AHWEU AIXLP ATHPR AYFIA CITATION .55 .GJ 8WZ A6W ABAWZ ABDBF ACUHS AI. B0M CAG CGR COF CUY CVF EAD EAS EBC EBD ECM EIF EMK EMOBN EPL J5H M41 NPM PHGZT SV3 TUS UDS VH1 X7M Y6R ZGI ~8M 3V. 7TO 7U9 7XB 8FE 8FH 8FK AZQEC DWQXO GNUQQ H94 K9. LK8 PHGZM PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 PUEGO 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-c570t-dbaa6c03be41f1370eea57d6d1a54657e5ee97c8785a85d8992f9288bec612b83 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 528 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000455095200007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0007-0920 1532-1827 |
| IngestDate | Tue Nov 04 01:53:03 EST 2025 Tue Oct 14 20:29:08 EDT 2025 Thu Oct 02 09:45:56 EDT 2025 Mon Oct 06 18:20:23 EDT 2025 Thu Apr 03 06:58:51 EDT 2025 Sat Nov 29 02:47:29 EST 2025 Tue Nov 18 22:15:09 EST 2025 Fri Feb 21 02:39:41 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c570t-dbaa6c03be41f1370eea57d6d1a54657e5ee97c8785a85d8992f9288bec612b83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Literature Review-3 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-1735-8722 |
| OpenAccessLink | https://hal.sorbonne-universite.fr/hal-01985551 |
| PMID | 30413828 |
| PQID | 2165066488 |
| PQPubID | 41855 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6325164 hal_primary_oai_HAL_hal_01985551v1 proquest_miscellaneous_2132229472 proquest_journals_2165066488 pubmed_primary_30413828 crossref_primary_10_1038_s41416_018_0327_z crossref_citationtrail_10_1038_s41416_018_0327_z springer_journals_10_1038_s41416_018_0327_z |
| PublicationCentury | 2000 |
| PublicationDate | 2019-01-00 |
| PublicationDateYYYYMMDD | 2019-01-01 |
| PublicationDate_xml | – month: 01 year: 2019 text: 2019-01-00 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | British journal of cancer |
| PublicationTitleAbbrev | Br J Cancer |
| PublicationTitleAlternate | Br J Cancer |
| PublicationYear | 2019 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Cancer Research UK |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Cancer Research UK |
| References | TaubeJanis MGalonJérômeShollLynette MRodigScott JCottrellTricia RGiraldoNicolas ABarasAlexander SPatelSanjay SAndersRobert ARimmDavid LCimino-MathewsAshleyImplications of the tumor immune microenvironment for staging and therapeuticsModern Pathology201731221423429192647613226310.1038/modpathol.2017.1561:CAS:528:DC%2BC2sXhvFKiurjP WoodsANDifferential expression of homing receptor ligands on tumor-associated vasculature that control CD8 effector T cell entryCancer Immunol. Res.20175106210731:CAS:528:DC%2BC2sXhvFWhsbvO29097419606952110.1158/2326-6066.CIR-17-0190 SilzleTTumor-associated fibroblasts recruit blood monocytes into tumor tissueEur. J. Immunol.200333131113201:CAS:528:DC%2BD3sXjvFyjs74%3D1273105610.1002/eji.200323057 McGranahanNClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeScience2016351146314691:CAS:528:DC%2BC28XksFCht70%3D26940869498425410.1126/science.aaf1490 UyttenhoveCEvidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenaseNat. Med.20039126912741:CAS:528:DC%2BD3sXns1Clu7c%3D1450228210.1038/nm934 PaulosCMMicrobial translocation augments the function of adoptively transferred self/tumor-specific CD8+T cells via TLR4 signalingJ. Clin. Invest.2007117219722041:CAS:528:DC%2BD2sXoslOns78%3D17657310192450010.1172/JCI32205 RuffiniEClinical significance of tumor-infiltrating lymphocytes in lung neoplasmsAnn. Thorac. Surg.2009873653711916173910.1016/j.athoracsur.2008.10.067 Chow L. Q. M., et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J. Clin. Oncol.34, 3838–3845 (2016). UramJNPD-1 blockade in tumors with mismatch repair deficiencyJ. Clin. Oncol.20153318_supplLBA10010.1200/jco.2015.33.18_suppl.lba100 MlecnikBIntegrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instabilityImmunity2016446987111:CAS:528:DC%2BC28Xktlahs7g%3D10.1016/j.immuni.2016.02.02526982367 LarkinJHodiFSWolchokJDCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN. Engl. J. Med.2015373127012712639807610.1056/NEJMoa15040301:CAS:528:DC%2BC2MXht12isr7M QianBZCCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasisNature20114752222251:CAS:528:DC%2BC3MXntFKrsb0%3D21654748320850610.1038/nature10138 MahmoudSMATumour-infiltrating macrophages and clinical outcome in breast cancerJ. Clin. Pathol.2012651591631:STN:280:DC%2BC387mtVynsA%3D%3D2204922510.1136/jclinpath-2011-200355 HuangYuhuiKimBetty Y. S.ChanCharles K.HahnStephen M.WeissmanIrving L.JiangWenImproving immune–vascular crosstalk for cancer immunotherapyNature Reviews Immunology20181831952031:CAS:528:DC%2BC1cXovVequg%3D%3D29332937592242210.1038/nri.2017.145 Gu-TrantienCCD4+ follicular helper T cell infiltration predicts breast cancer survivalJ. Clin. Invest.2013123287328921:CAS:528:DC%2BC3sXhtFWjtr3J23778140369655610.1172/JCI67428 Pylayeva-GuptaYLeeKEHajduCHMillerGBar-SagiDOncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasiaCancer Cell2012218368471:CAS:528:DC%2BC38XosVeit7c%3D22698407372151010.1016/j.ccr.2012.04.024 LathropSKPeripheral education of the immune system by colonic commensal microbiotaNature20114782502541:CAS:528:DC%2BC3MXht1Slu7nE21937990319290810.1038/nature10434 WeberDJKorolukLDPhillipsCNguyenTProffitWRClinical effectiveness and efficiency of customized vs. conventional preadjusted bracket systemsJ. Clin. Orthod.20134726126623660822 de KruijfEMTumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patientsBreast Cancer Res. Treat.20131423553642419765910.1007/s10549-013-2752-21:CAS:528:DC%2BC3sXhslGltr%2FN CrowsonANMagroCMMihmMCPrognosticators of melanoma, the melanoma report, and the sentinel lymph nodeMod. Pathol.200619S71S871644671710.1038/modpathol.3800517 HerbstRSPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet Lond. Engl.2016387154015501:CAS:528:DC%2BC2MXitVGrtLzI10.1016/S0140-6736(15)01281-7 SprangerSDensity of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanomaProc. Natl. Acad. Sci. USA2016113E7759E77681:CAS:528:DC%2BC28XhvVCitbjL2783702010.1073/pnas.16093761135137753 ApoloABAvelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib studyJ. Clin. Oncol.201735211721241:CAS:528:DC%2BC1cXhvFKnsLjE28375787549305110.1200/JCO.2016.71.6795 ViaudSThe intestinal microbiota modulates the anticancer immune effects of cyclophosphamideScience20133429719761:CAS:528:DC%2BC3sXhsl2htL3P24264990404894710.1126/science.1240537 SmithPMThe microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasisScience20133415695731:CAS:528:DC%2BC3sXhtFyjsr3P10.1126/science.124116523828891 ChenPLAnalysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockadeCancer Discov.2016682783727301722508298410.1158/2159-8290.CD-15-15451:CAS:528:DC%2BC28Xht12mtbbP ChaeYKMutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinomaOncotarget201897949796029487705 JainRKAntiangiogenesis strategies revisited: from starving tumors to alleviating hypoxiaCancer Cell2014266056221:CAS:528:DC%2BC2cXhvFSmt73F25517747426983010.1016/j.ccell.2014.10.006 CasbonAJInvasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophilsProc. Natl. Acad. Sci. USA2015112E566E5751:CAS:528:DC%2BC2MXhsVeiu70%3D2562450010.1073/pnas.14249271124330753 FletcherMatthewRamirezMaria E.SierraRosa A.RaberPatrickThevenotPaulAl-KhamiAmir A.Sanchez-PinoDulfaryHernandezClaudiaWyczechowskaDorota D.OchoaAugusto C.RodriguezPaulo C.l-Arginine Depletion Blunts Antitumor T-cell Responses by Inducing Myeloid-Derived Suppressor CellsCancer Research201475227528325406192429756510.1158/0008-5472.CAN-14-14911:CAS:528:DC%2BC2MXnslWjtA%3D%3D WelshTJMacrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non–small-cell lung cancerJ. Clin. Oncol.200523895989671621993410.1200/JCO.2005.01.4910 de ChaisemartinLCharacterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancerCancer Res.201171639163992190040310.1158/0008-5472.CAN-11-09521:CAS:528:DC%2BC3MXhtlSltLjP HiraokaKConcurrent infiltration by CD8+T cells and CD4+T cells is a favourable prognostic factor in non-small-cell lung carcinomaBr. J. Cancer2006942752801:CAS:528:DC%2BD28XmvVynsQ%3D%3D16421594236110310.1038/sj.bjc.6602934 GiannakisMGenomic correlates of immune-cell infiltrates in colorectal carcinomaCell Rep.2016158578651:CAS:528:DC%2BC28XmtFCiuro%3D27149842485035710.1016/j.celrep.2016.03.075 ArpaiaNMetabolites produced by commensal bacteria promote peripheral regulatory T cell generationNature20135044514551:CAS:528:DC%2BC3sXhvFOmtrrJ24226773386988410.1038/nature12726 CoelhoMAOncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNAImmunity20174710831099.e61:CAS:528:DC%2BC2sXhvFKgsrrI29246442574617010.1016/j.immuni.2017.11.016 MohammedZMAGoingJJEdwardsJElsbergerBMcMillanDCThe relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancerBr. J. Cancer2013109167616841:CAS:528:DC%2BC3sXhsVyqtr%2FO23982600377700210.1038/bjc.2013.493 Ene-ObongAActivated pancreatic stellate cells sequester CD8+T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinomaGastroenterology2013145112111321:CAS:528:DC%2BC3sXhs1OqsrfF2389197210.1053/j.gastro.2013.07.025 HugoWGenomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanomaCell201616535441:CAS:528:DC%2BC28XksVKrsbw%3D26997480480843710.1016/j.cell.2016.02.065 Vujkovic-CvijinIDysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolismSci. Transl. Med.20135193ra9123843452409429410.1126/scitranslmed.30064381:CAS:528:DC%2BC3sXht1SqtbbE GengYPrognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysisCell Physiol. Biochem.201537156015711:CAS:528:DC%2BC2MXhslylu7rK2651314310.1159/000438523 ClarkWHModel predicting survival in stage I melanoma based on tumor progressionJ. Natl. Cancer Inst.19898118931904259316610.1093/jnci/81.24.1893 CalderaroJHistological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classificationJ. Hepatol.2017677277381:CAS:528:DC%2BC2sXhtVGnu7fM2853299510.1016/j.jhep.2017.05.014 ParkMHLeeJSYoonJHHigh expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+T cells, natural killer cells, and dendritic cells in breast carcinomaJ. Surg. Oncol.20121063863921:CAS:528:DC%2BC38XhtFOqtrjM2242219510.1002/jso.23095 Balar A. V., et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet389, 67–76 (2017). GocJDendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+T cellsCancer Res.2014747057151:CAS:528:DC%2BC2cXhvVSmsrc%3D2436688510.1158/0008-5472.CAN-13-1342 MurisJJFPrognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomasLeukemia2004185895961:CAS:528:DC%2BD2cXhsV2qs7k%3D1471228610.1038/sj.leu.2403240 KarimiKInmanMDBienenstockJForsythePLactobacillus r E Becht (327_CR94) 2016; 39 C Robert (327_CR120) 2015; 372 Yuhui Huang (327_CR34) 2018; 18 PL Chen (327_CR150) 2016; 6 MD Buck (327_CR51) 2017; 169 DW Scott (327_CR81) 2013; 31 K Hiraoka (327_CR104) 2006; 94 AN Crowson (327_CR86) 2006; 19 O Nakano (327_CR92) 2001; 61 ZMA Mohammed (327_CR97) 2013; 109 Z Chen (327_CR99) 2014; 9 G Dranoff (327_CR3) 2004; 4 IV Pinchuk (327_CR46) 2008; 135 Y Furusawa (327_CR65) 2013; 504 SL Topalian (327_CR115) 2016; 16 AN Woods (327_CR38) 2017; 5 MS Lawrence (327_CR144) 2013; 499 K Muro (327_CR142) 2016; 17 B Routy (327_CR71) 2018; 359 MA Coelho (327_CR30) 2017; 47 TN Schumacher (327_CR143) 2015; 348 JM Taube (327_CR153) 2015; 21 MJ Campbell (327_CR101) 2011; 128 Tae-Min Kim (327_CR18) 2013; 155 E Becht (327_CR93) 2015; 4 MC Dieu-Nosjean (327_CR42) 2014; 35 K Atarashi (327_CR62) 2013; 500 V Gopalakrishnan (327_CR73) 2018; 359 N Arpaia (327_CR64) 2013; 504 CM Ohri (327_CR110) 2009; 33 SL Topalian (327_CR114) 2017; 318 B Mlecnik (327_CR20) 2016; 44 AJ Casbon (327_CR28) 2015; 112 SL Topalian (327_CR116) 2012; 366 W Hugo (327_CR149) 2016; 165 Y Belkaid (327_CR58) 2014; 157 K Karimi (327_CR60) 2009; 179 C Massard (327_CR136) 2016; 34 RS Herbst (327_CR117) 2014; 515 CH Chang (327_CR54) 2015; 162 327_CR133 MR Nazareth (327_CR45) 2007; 178 NA Giraldo (327_CR2) 2014; 27 PC Tumeh (327_CR151) 2014; 515 WC Wu (327_CR27) 2014; 111 S Viaud (327_CR67) 2013; 342 O Kawai (327_CR105) 2008; 113 DJ Weber (327_CR121) 2013; 47 RJ Motzer (327_CR139) 2015; 33 S Spranger (327_CR21) 2015; 523 CS Grasso (327_CR23) 2018; 8 I Vujkovic-Cvijin (327_CR59) 2013; 5 LB Alexandrov (327_CR155) 2013; 500 Y Pylayeva-Gupta (327_CR26) 2012; 21 H Borghaei (327_CR124) 2015; 373 CG Clemente (327_CR83) 1996; 77 SK Lathrop (327_CR61) 2011; 478 EB Garon (327_CR129) 2015; 372 DT Le (327_CR152) 2015; 372 NA Rizvi (327_CR145) 2015; 348 J Brahmer (327_CR125) 2015; 373 NE Thomas (327_CR85) 2013; 31 327_CR141 J Calderaro (327_CR24) 2017; 67 L Fehrenbacher (327_CR130) 2016; 387 C Murdoch (327_CR11) 2008; 8 L Chaisemartin de (327_CR5) 2011; 71 P Carmeliet (327_CR33) 2000; 407 SM Pyonteck (327_CR10) 2013; 19 DH Dapito (327_CR66) 2012; 21 H Takahashi (327_CR48) 2016; 8 S Hernández-Prieto (327_CR113) 2015; 17 SB Coffelt (327_CR29) 2016; 16 JD Wolchok (327_CR122) 2017; 377 SMA Mahmoud (327_CR103) 2012; 65 NJ Llosa (327_CR19) 2015; 5 NA Giraldo (327_CR78) 2017; 23 DF McDermott (327_CR140) 2016; 34 JE Rosenberg (327_CR134) 2016; 387 N Iida (327_CR69) 2013; 342 J Galon (327_CR90) 2016; 34 AN Seo (327_CR98) 2013; 109 A Ene-Obong (327_CR49) 2013; 145 C Uyttenhove (327_CR55) 2003; 9 M Yarchoan (327_CR16) 2017; 17 AB Apolo (327_CR138) 2017; 35 B Vogelstein (327_CR14) 2013; 339 SZ Josefowicz (327_CR12) 2012; 30 RJ Buckanovich (327_CR36) 2008; 14 S Gettinger (327_CR123) 2016; 34 MD Buck (327_CR50) 2015; 212 Y Kojima (327_CR44) 2010; 107 YA Vano (327_CR154) 2018; 51 SN Gettinger (327_CR126) 2015; 33 T Powles (327_CR135) 2014; 515 JJF Muris (327_CR80) 2004; 18 J Hamzah (327_CR40) 2008; 453 TJ Welsh (327_CR111) 2005; 23 MG Morvan (327_CR7) 2016; 16 E Ruffini (327_CR106) 2009; 87 OAW Haabeth (327_CR8) 2011; 2 WH Fridman (327_CR74) 2012; 12 327_CR79 J Goc (327_CR6) 2014; 74 Y Geng (327_CR109) 2015; 37 NA Giraldo (327_CR77) 2015; 21 G Erdag (327_CR87) 2012; 72 S Spranger (327_CR32) 2016; 113 CM Cham (327_CR52) 2005; 174 D Bouskra (327_CR57) 2008; 456 T Powles (327_CR137) 2017; 3 YK Chae (327_CR31) 2018; 9 JD Peske (327_CR41) 2015; 6 JN Uram (327_CR146) 2015; 33 MC Dieu-Nosjean (327_CR4) 2016; 271 EM Kruijf de (327_CR96) 2013; 142 J Larkin (327_CR118) 2015; 373 RM Kortlever (327_CR25) 2017; 171 T Silzle (327_CR47) 2003; 33 PM Smith (327_CR63) 2013; 341 CM Paulos (327_CR68) 2007; 117 WH Clark (327_CR82) 1989; 81 NA Rizvi (327_CR127) 2015; 16 NA Giraldo (327_CR15) 2015; 467 A Kilic (327_CR107) 2011; 167 RS Herbst (327_CR128) 2016; 387 N McGranahan (327_CR148) 2016; 351 DG DeNardo (327_CR102) 2011; 1 DT Fisher (327_CR37) 2011; 121 DT Le (327_CR147) 2017; 357 A Mantovani (327_CR13) 2017; 14 C Germain (327_CR43) 2014; 189 V Matson (327_CR72) 2018; 359 F Azimi (327_CR84) 2012; 30 327_CR88 RK Jain (327_CR35) 2014; 26 Matthew Fletcher (327_CR53) 2014; 75 WH Fridman (327_CR76) 2017; 14 M Giannakis (327_CR17) 2016; 15 P Sharma (327_CR132) 2016; 17 E Becht (327_CR22) 2016; 22 Janis M Taube (327_CR89) 2017; 31 327_CR91 MH Park (327_CR95) 2012; 106 BZ Qian (327_CR9) 2011; 475 H Harlin (327_CR39) 2009; 69 E Becht (327_CR75) 2016; 130 M Lohr (327_CR112) 2013; 333 H Liu (327_CR108) 2012; 61 K Honda (327_CR56) 2016; 535 E Becht (327_CR156) 2016; 17 327_CR1 M Vétizou (327_CR70) 2015; 350 C Gu-Trantien (327_CR100) 2013; 123 JL Gulley (327_CR131) 2017; 18 JS Weber (327_CR119) 2015; 16 |
| References_xml | – reference: BechtEEstimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expressionGenome Biol.20161727765066507388910.1186/s13059-016-1070-51:CAS:528:DC%2BC2sXhvF2rt7fJ – reference: Hernández-PrietoSA 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancerClin. Transl. Oncol.2015173303382530140410.1007/s12094-014-1235-11:CAS:528:DC%2BC2cXhslOjsLfI – reference: SprangerSDensity of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanomaProc. Natl. Acad. Sci. USA2016113E7759E77681:CAS:528:DC%2BC28XhvVCitbjL2783702010.1073/pnas.16093761135137753 – reference: IidaNCommensal bacteria control cancer response to therapy by modulating the tumor microenvironmentScience20133429679701:CAS:528:DC%2BC3sXhsl2htL3M24264989670953210.1126/science.1240527 – reference: HaabethOAWInflammation driven by tumour-specific Th1 cells protects against B-cell cancerNat. Commun.201122140720610.1038/ncomms12391:CAS:528:DC%2BC3MXlt1Wrs7Y%3D – reference: CoffeltSBWellensteinMDde VisserKENeutrophils in cancer: neutral no moreNat. Rev. Cancer2016164314461:CAS:528:DC%2BC28XpsFCltbs%3D2728224910.1038/nrc.2016.52 – reference: GermainCPresence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancerAm. J. Respir. Crit. Care. Med.20141898328441:CAS:528:DC%2BC2cXpsVahu70%3D2448423610.1164/rccm.201309-1611OC – reference: RobertCNivolumab in previously untreated melanoma without BRAF mutationN. Engl. J. Med.20153723203301:CAS:528:DC%2BC2MXisFGqsLg%3D2539955210.1056/NEJMoa1412082 – reference: ChangCHMetabolic competition in the tumor microenvironment is a driver of cancer progressionCell2015162122912411:CAS:528:DC%2BC2MXhsVajs7%2FI26321679486436310.1016/j.cell.2015.08.016 – reference: WoodsANDifferential expression of homing receptor ligands on tumor-associated vasculature that control CD8 effector T cell entryCancer Immunol. Res.20175106210731:CAS:528:DC%2BC2sXhvFWhsbvO29097419606952110.1158/2326-6066.CIR-17-0190 – reference: MuroKPembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialLancet Oncol.2016177177261:CAS:528:DC%2BC28XntlSmt7w%3D2715749110.1016/S1470-2045(16)00175-3 – reference: BechtEGiraldoNADieu-NosjeanMCSautès-FridmanCFridmanWHCancer immune contexture and immunotherapyCurr. Opin. Immunol.2016397131:CAS:528:DC%2BC2MXitVShs73K2670893710.1016/j.coi.2015.11.009 – reference: OhriCMShikotraAGreenRHWallerDABraddingPMacrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survivalEur. Respir. J.2009331181261:STN:280:DC%2BD1M%2FkslWktQ%3D%3D1911822510.1183/09031936.00065708 – reference: AtarashiKTreg induction by a rationally selected mixture of Clostridia strains from the human microbiotaNature20135002322361:CAS:528:DC%2BC3sXhtFShsbfJ10.1038/nature1233123842501 – reference: MassardCSafety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancerJ. Clin. Oncol.201634311931251:CAS:528:DC%2BC28XhvFertrzP27269937556969010.1200/JCO.2016.67.9761 – reference: RoutyBGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsScience201835991971:CAS:528:DC%2BC1cXjslOrsw%3D%3D10.1126/science.aan370629097494 – reference: Pagès F., et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391:2128–2139 (2018). – reference: ChenZIntratumoral CD8+cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancerPLoS. ONE20149e9547524743335399063710.1371/journal.pone.00954751:CAS:528:DC%2BC2cXhsFensbvM – reference: DapitoDHPromotion of hepatocellular carcinoma by the intestinal microbiota and TLR4Cancer Cell2012215045161:CAS:528:DC%2BC38XlvVSmu7s%3D22516259333200010.1016/j.ccr.2012.02.007 – reference: MatsonVThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patientsScience20183591041081:CAS:528:DC%2BC1cXjslOksg%3D%3D29302014670735310.1126/science.aao3290 – reference: HarlinHChemokine expression in melanoma metastases associated with CD8+T-cell recruitmentCancer Res.200969307730851:CAS:528:DC%2BD1MXjvVWitr8%3D1929319010.1158/0008-5472.CAN-08-2281 – reference: UyttenhoveCEvidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenaseNat. Med.20039126912741:CAS:528:DC%2BD3sXns1Clu7c%3D1450228210.1038/nm934 – reference: WuWCCirculating hematopoietic stem and progenitor cells are myeloid-biased in cancer patientsProc. Natl. Acad. Sci. USA2014111422142261:CAS:528:DC%2BC2cXjtl2gsLk%3D2459163810.1073/pnas.13207531113964061 – reference: HuangYuhuiKimBetty Y. S.ChanCharles K.HahnStephen M.WeissmanIrving L.JiangWenImproving immune–vascular crosstalk for cancer immunotherapyNature Reviews Immunology20181831952031:CAS:528:DC%2BC1cXovVequg%3D%3D29332937592242210.1038/nri.2017.145 – reference: QianBZCCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasisNature20114752222251:CAS:528:DC%2BC3MXntFKrsb0%3D21654748320850610.1038/nature10138 – reference: KawaiOPredominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancerCancer2008113138713951:CAS:528:DC%2BD1cXhtFyls7rL1867123910.1002/cncr.23712 – reference: GiraldoNABechtEVanoYSautès-FridmanCFridmanWHThe immune response in cancer: from immunology to pathology to immunotherapyVirchows Arch. Int J. Pathol.20154671271351:CAS:528:DC%2BC2MXhtVegur%2FL10.1007/s00428-015-1787-7 – reference: Vujkovic-CvijinIDysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolismSci. Transl. Med.20135193ra9123843452409429410.1126/scitranslmed.30064381:CAS:528:DC%2BC3sXht1SqtbbE – reference: de ChaisemartinLCharacterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancerCancer Res.201171639163992190040310.1158/0008-5472.CAN-11-09521:CAS:528:DC%2BC3MXhtlSltLjP – reference: BechtEPrognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC)Oncoimmunology20154e104980426587318463588810.1080/2162402X.2015.10498041:CAS:528:DC%2BC28XhsFKit7c%3D – reference: TaubeJanis MGalonJérômeShollLynette MRodigScott JCottrellTricia RGiraldoNicolas ABarasAlexander SPatelSanjay SAndersRobert ARimmDavid LCimino-MathewsAshleyImplications of the tumor immune microenvironment for staging and therapeuticsModern Pathology201731221423429192647613226310.1038/modpathol.2017.1561:CAS:528:DC%2BC2sXhvFKiurjP – reference: WolchokJDOverall survival with combined nivolumab and ipilimumab in advanced melanomaN. Engl. J. Med.2017377134513561:CAS:528:DC%2BC2sXhs1Git73I28889792570677810.1056/NEJMoa1709684 – reference: TopalianSLTargeting immune checkpoints in cancer therapyJAMA2017318164716482888563910.1001/jama.2017.14155 – reference: Dieu-NosjeanMCGocJGiraldoNASautès-FridmanCFridmanWHTertiary lymphoid structures in cancer and beyondTrends Immunol.2014355715801:CAS:528:DC%2BC2cXhs1ygs7%2FJ2544349510.1016/j.it.2014.09.006 – reference: Pylayeva-GuptaYLeeKEHajduCHMillerGBar-SagiDOncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasiaCancer Cell2012218368471:CAS:528:DC%2BC38XosVeit7c%3D22698407372151010.1016/j.ccr.2012.04.024 – reference: WelshTJMacrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non–small-cell lung cancerJ. Clin. Oncol.200523895989671621993410.1200/JCO.2005.01.4910 – reference: BorghaeiHNivolumab versus docetaxel in advanced nonsquamous-cell non-small-cell lung cancerN. Engl. J. Med.2015373162716391:CAS:528:DC%2BC28XjsFyitL0%3D26412456570593610.1056/NEJMoa1507643 – reference: CarmelietPJainRKAngiogenesis in cancer and other diseasesNature20004072492571:CAS:528:DC%2BD3cXmvVSls74%3D1100106810.1038/35025220 – reference: ClementeCGPrognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanomaCancer199677130313101:STN:280:DyaK287pslChtA%3D%3D10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-58608507 – reference: NakanoOProliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunityCancer Res.200161513251361:CAS:528:DC%2BD3MXltVequ7Y%3D11431351 – reference: GengYPrognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysisCell Physiol. Biochem.201537156015711:CAS:528:DC%2BC2MXhslylu7rK2651314310.1159/000438523 – reference: LeDTMismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience20173574094131:CAS:528:DC%2BC2sXht1aksLnN28596308557614210.1126/science.aan6733 – reference: CrowsonANMagroCMMihmMCPrognosticators of melanoma, the melanoma report, and the sentinel lymph nodeMod. Pathol.200619S71S871644671710.1038/modpathol.3800517 – reference: GettingerSNivolumab monotherapyfor first-line treatment of advanced non-small-cell lung cancerJ. Clin. Oncol.201634298029871:CAS:528:DC%2BC28XhvFertrjM27354485556969210.1200/JCO.2016.66.9929 – reference: TopalianSLTaubeJMAndersRAPardollDMMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapyNat. Rev. Cancer2016162752871:CAS:528:DC%2BC28XmtVOrurc%3D27079802538193810.1038/nrc.2016.36 – reference: Ene-ObongAActivated pancreatic stellate cells sequester CD8+T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinomaGastroenterology2013145112111321:CAS:528:DC%2BC3sXhs1OqsrfF2389197210.1053/j.gastro.2013.07.025 – reference: BuckMDO’SullivanDPearceELT cell metabolism drives immunityJ. Exp. Med.2015212134513601:CAS:528:DC%2BC2MXhsVyhsb7L26261266454805210.1084/jem.20151159 – reference: BouskraDLymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasisNature20084565075101:CAS:528:DC%2BD1cXhsVegur7N10.1038/nature0745018987631 – reference: MohammedZMAGoingJJEdwardsJElsbergerBMcMillanDCThe relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancerBr. J. Cancer2013109167616841:CAS:528:DC%2BC3sXhsVyqtr%2FO23982600377700210.1038/bjc.2013.493 – reference: Gu-TrantienCCD4+ follicular helper T cell infiltration predicts breast cancer survivalJ. Clin. Invest.2013123287328921:CAS:528:DC%2BC3sXhtFWjtr3J23778140369655610.1172/JCI67428 – reference: CampbellMJProliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcomeBreast Cancer Res. Treat.20111287037112084252610.1007/s10549-010-1154-y – reference: KimTae-MinLairdPeter W.ParkPeter J.The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer GenomesCell201315548588681:CAS:528:DC%2BC3sXhslCltrrN10.1016/j.cell.2013.10.01524209623 – reference: NazarethMRCharacterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cellsJ. Immunol.2007178555255621:CAS:528:DC%2BD2sXktlWiurs%3D1744293710.4049/jimmunol.178.9.5552 – reference: PeskeJDEffector lymphocyte-induced lymph node-like vasculature enables naive T cell entry into tumours and enhanced anti-tumour immunityNat. Commun.201561:CAS:528:DC%2BC2MXhtF2kt7bJ2596833410.1038/ncomms8114 – reference: PyonteckSMCSF-1R inhibition alters macrophage polarization and blocks glioma progressionNat. Med.201319126412721:CAS:528:DC%2BC3sXhsV2jsr3N24056773384072410.1038/nm.3337 – reference: LlosaNJThe vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpointsCancer Discov.2015543511:CAS:528:DC%2BC2MXhtFCntbo%3D2535868910.1158/2159-8290.CD-14-0863 – reference: AzimiFTumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanomaJ. Clin. Oncol.201230267826832271185010.1200/JCO.2011.37.8539 – reference: HiraokaKConcurrent infiltration by CD8+T cells and CD4+T cells is a favourable prognostic factor in non-small-cell lung carcinomaBr. J. Cancer2006942752801:CAS:528:DC%2BD28XmvVynsQ%3D%3D16421594236110310.1038/sj.bjc.6602934 – reference: LathropSKPeripheral education of the immune system by colonic commensal microbiotaNature20114782502541:CAS:528:DC%2BC3MXht1Slu7nE21937990319290810.1038/nature10434 – reference: ErdagGImmunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanomaCancer Res.201272107010801:CAS:528:DC%2BC38Xjt1Wju7Y%3D22266112330681310.1158/0008-5472.CAN-11-3218 – reference: Chow L. Q. M., et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J. Clin. Oncol.34, 3838–3845 (2016). – reference: GopalakrishnanVGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patientsScience2018359971031:CAS:528:DC%2BC1cXjslOrsA%3D%3D10.1126/science.aan423629097493 – reference: GiraldoNATumor-infiltrating and peripheral blood t-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinomaClin. Cancer Res.201723441644281:CAS:528:DC%2BC2sXht1Ghu7jJ2821336610.1158/1078-0432.CCR-16-2848 – reference: FisherDTIL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cellsJ. Clin. Invest.2011121384638591:CAS:528:DC%2BC3MXht12ht7jI21926464319545510.1172/JCI44952 – reference: TakahashiHCancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophagesOncotarget20168863386475352428 – reference: BuckMDSowellRTKaechSMPearceELMetabolic Instruction of ImmunityCell20171695705861:CAS:528:DC%2BC2sXnt1CmsLc%3D28475890564802110.1016/j.cell.2017.04.004 – reference: GettingerSNOverall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancerJ. Clin. Oncol. J. Am. Soc. Clin. Oncol.201533200420121:CAS:528:DC%2BC2MXhsFKmt7rJ10.1200/JCO.2014.58.3708 – reference: VanoYAPetitprezFGiraldoNAFridmanWHSautès-FridmanCImmune-based identification of cancer patients at high risk of progressionCurr. Opin. Immunol.201851971021:CAS:528:DC%2BC1cXksVems7g%3D2955449610.1016/j.coi.2018.03.005 – reference: PowlesTMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature20145155585621:CAS:528:DC%2BC2cXitFamsrjE10.1038/nature1390425428503 – reference: CalderaroJHistological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classificationJ. Hepatol.2017677277381:CAS:528:DC%2BC2sXhtVGnu7fM2853299510.1016/j.jhep.2017.05.014 – reference: ClarkWHModel predicting survival in stage I melanoma based on tumor progressionJ. Natl. Cancer Inst.19898118931904259316610.1093/jnci/81.24.1893 – reference: ArpaiaNMetabolites produced by commensal bacteria promote peripheral regulatory T cell generationNature20135044514551:CAS:528:DC%2BC3sXhvFOmtrrJ24226773386988410.1038/nature12726 – reference: RizviNACancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerScience20153481241281:CAS:528:DC%2BC2MXls1Wmtbg%3D25765070499315410.1126/science.aaa1348 – reference: MantovaniAMarchesiFMalesciALaghiLAllavenaPTumour-associated macrophages as treatment targets in oncologyNat. Rev. Clin. Oncol.2017143994161:CAS:528:DC%2BC2sXhsFGlsbs%3D28117416548060010.1038/nrclinonc.2016.217 – reference: LarkinJHodiFSWolchokJDCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN. Engl. J. Med.2015373127012712639807610.1056/NEJMoa15040301:CAS:528:DC%2BC2MXht12isr7M – reference: AlexandrovLBSignatures of mutational processes in human cancerNature20135004154211:CAS:528:DC%2BC3sXhtlWjur7M23945592377639010.1038/nature12477 – reference: WeberDJKorolukLDPhillipsCNguyenTProffitWRClinical effectiveness and efficiency of customized vs. conventional preadjusted bracket systemsJ. Clin. Orthod.20134726126623660822 – reference: BelkaidYHandTRole of the microbiota in Immunity and inflammationCell20141571211411:CAS:528:DC%2BC2cXmtVCqsL8%3D24679531405676510.1016/j.cell.2014.03.011 – reference: MotzerRJNivolumab for metastatic renal cell carcinoma: results of a randomized phase II trialJ. Clin. Oncol.201533143014371:CAS:528:DC%2BC2MXpvFahsbY%3D2545245210.1200/JCO.2014.59.0703 – reference: GiannakisMGenomic correlates of immune-cell infiltrates in colorectal carcinomaCell Rep.2016158578651:CAS:528:DC%2BC28XmtFCiuro%3D27149842485035710.1016/j.celrep.2016.03.075 – reference: SharmaPNivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialLancet Oncol.201617159015981:CAS:528:DC%2BC28Xhs1GnsbjM27733243564805410.1016/S1470-2045(16)30496-X – reference: PowlesTEfficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label studyJAMA Oncol.20173e172411e17241128817753582428810.1001/jamaoncol.2017.2411 – reference: KortleverRMMyc cooperates with Ras by programming inflammation and immune suppressionCell2017171130113151:CAS:528:DC%2BC2sXhvFWmsbrN29195074572039310.1016/j.cell.2017.11.013 – reference: DranoffGCytokines in cancer pathogenesis and cancer therapyNat. Rev. Cancer2004411221:CAS:528:DC%2BD2cXos1Wjtg%3D%3D1470802410.1038/nrc1252 – reference: MurdochCMuthanaMCoffeltSBLewisCEThe role of myeloid cells in the promotion of tumour angiogenesisNat. Rev. Cancer200886186311:CAS:528:DC%2BD1cXovV2lsrY%3D1863335510.1038/nrc2444 – reference: MahmoudSMATumour-infiltrating macrophages and clinical outcome in breast cancerJ. Clin. Pathol.2012651591631:STN:280:DC%2BC387mtVynsA%3D%3D2204922510.1136/jclinpath-2011-200355 – reference: BrahmerJNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN. Engl. J. Med.20153731231351:CAS:528:DC%2BC2MXht12qu7%2FJ26028407468140010.1056/NEJMoa1504627 – reference: ViaudSThe intestinal microbiota modulates the anticancer immune effects of cyclophosphamideScience20133429719761:CAS:528:DC%2BC3sXhsl2htL3P24264990404894710.1126/science.1240537 – reference: LohrMThe prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancerCancer Lett.20133332222281:CAS:528:DC%2BC3sXjvFClt74%3D2337022410.1016/j.canlet.2013.01.036 – reference: McGranahanNClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeScience2016351146314691:CAS:528:DC%2BC28XksFCht70%3D26940869498425410.1126/science.aaf1490 – reference: VogelsteinBCancer genome landscapesScience2013339154615581:CAS:528:DC%2BC3sXksFOhsb0%3D23539594374988010.1126/science.1235122 – reference: MurisJJFPrognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomasLeukemia2004185895961:CAS:528:DC%2BD2cXhsV2qs7k%3D1471228610.1038/sj.leu.2403240 – reference: GaronEBPembrolizumab for the treatment of non-small-cell lung cancerN. Engl. J. Med.2015372201820282589117410.1056/NEJMoa1501824 – reference: LeDTPD-1 blockade in tumors with mismatch-repair deficiencyN. Engl. J. Med.2015372250925201:CAS:528:DC%2BC2MXhtFyrsbrI26028255448113610.1056/NEJMoa1500596 – reference: YarchoanMJohnson IiiBALutzERLaheruDAJaffeeEMTargeting neoantigens to augment anti-tumour immunityNat. Rev. Cancer2017172092221:CAS:528:DC%2BC2sXkt1Ontrc%3D28233802557580110.1038/nrc.2016.154 – reference: TaubeJMDifferential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockadeClin. Cancer Res.20152139691:CAS:528:DC%2BC2MXhsVCrsb7P25944800455823710.1158/1078-0432.CCR-15-0244 – reference: de KruijfEMTumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patientsBreast Cancer Res. Treat.20131423553642419765910.1007/s10549-013-2752-21:CAS:528:DC%2BC3sXhslGltr%2FN – reference: Giraldo N.A., Taube J.M. PD-L1 and Other Immunological Diagnosis Tools. In: Zitvogel L., Kroemer G. (eds) Oncoimmunology (Springer, Cham, 2018). – reference: KilicALandreneauRJLuketichJDPennathurASchuchertMJDensity of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors1J. Surg. Res.20111672072101989667710.1016/j.jss.2009.08.029 – reference: HondaKLittmanDRThe microbiota in adaptive immune homeostasis and diseaseNature201653575841:CAS:528:DC%2BC28XhtFensLzK2738398210.1038/nature18848 – reference: CoelhoMAOncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNAImmunity20174710831099.e61:CAS:528:DC%2BC2sXhvFKgsrrI29246442574617010.1016/j.immuni.2017.11.016 – reference: ChamCMGajewskiTFGlucose availability regulates IFN-γ production and p70S6 kinase activation in CD8+ effector T cellsJ. Immunol.2005174467046771:CAS:528:DC%2BD2MXivFKitLw%3D1581469110.4049/jimmunol.174.8.4670 – reference: GocJDendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+T cellsCancer Res.2014747057151:CAS:528:DC%2BC2cXhvVSmsrc%3D2436688510.1158/0008-5472.CAN-13-1342 – reference: FletcherMatthewRamirezMaria E.SierraRosa A.RaberPatrickThevenotPaulAl-KhamiAmir A.Sanchez-PinoDulfaryHernandezClaudiaWyczechowskaDorota D.OchoaAugusto C.RodriguezPaulo C.l-Arginine Depletion Blunts Antitumor T-cell Responses by Inducing Myeloid-Derived Suppressor CellsCancer Research201475227528325406192429756510.1158/0008-5472.CAN-14-14911:CAS:528:DC%2BC2MXnslWjtA%3D%3D – reference: LiuHTumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancerCancer Immunol. Immunother.201261184918561:CAS:528:DC%2BC38Xhtl2rtbnP2245675710.1007/s00262-012-1231-7 – reference: FehrenbacherLAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet2016387183718461:CAS:528:DC%2BC28XktVOltrs%3D10.1016/S0140-6736(16)00587-026970723 – reference: FridmanWHPagèsFSautès-FridmanCGalonJThe immune contexture in human tumours: impact on clinical outcomeNat. Rev. Cancer2012122983061:CAS:528:DC%2BC38Xjslersb4%3D10.1038/nrc324522419253 – reference: MlecnikBIntegrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instabilityImmunity2016446987111:CAS:528:DC%2BC28Xktlahs7g%3D10.1016/j.immuni.2016.02.02526982367 – reference: JosefowiczSZLuLFRudenskyAYRegulatory T cells: mechanisms of differentiation and functionAnnu. Rev. Immunol.2012305315641:CAS:528:DC%2BC38XmsVKmurs%3D22224781606637410.1146/annurev.immunol.25.022106.141623 – reference: Cancer Protocol Templates—College of American Pathologists [Internet]. (cited 8 March 2018]. Available from: http://www.cap.org/web/oracle/webcenter/portalapp/pagehierarchy/cancer_protocol_templates.jspx?_adf.ctrl-state=162jexggao_4&_afrLoop=374861371580044#!%40%40%3F_afrLoop%3D374861371580044%26_adf.ctrl-state%3D1chvg2427o_4. – reference: PinchukIVPD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+T-cell activityGastroenterology2008135122812371:CAS:528:DC%2BD1cXht12lurrL1876027810.1053/j.gastro.2008.07.016 – reference: RosenbergJEAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialLancet2016387190919201:CAS:528:DC%2BC28XjslGmu7w%3D26952546548024210.1016/S0140-6736(16)00561-4 – reference: SchumacherTNSchreiberRDNeoantigens in cancer immunotherapyScience201534869741:CAS:528:DC%2BC2MXls1Wmurc%3D2583837510.1126/science.aaa4971 – reference: KojimaYAutocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblastsProc. Natl. Acad. Sci.201010720009200141:CAS:528:DC%2BC3cXhsVyitL3K2104165910.1073/pnas.10138051072993333 – reference: TumehPCPD-1 blockade induces responses by inhibiting adaptive immune resistanceNature20145155685711:CAS:528:DC%2BC2cXitFanu7jL25428505424641810.1038/nature13954 – reference: GalonJValidation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: results of a worldwide consortium-based analysis of 1,336 patientsJ. Clin. Oncol.2016343500350010.1200/JCO.2016.34.15_suppl.3500 – reference: DeNardoDGLeukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapyCancer Discov.2011154671:CAS:528:DC%2BC3MXpsVylsbo%3D22039576320352410.1158/2159-8274.CD-10-0028 – reference: GiraldoNAOrchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancerClin. Cancer Res.201521303130401:CAS:528:DC%2BC2MXhtFCktrnO2568816010.1158/1078-0432.CCR-14-2926 – reference: HamzahJVascular normalization in Rgs5-deficient tumours promotes immune destructionNature20084534104141:CAS:528:DC%2BD1cXlvV2qtL4%3D10.1038/nature0686818418378 – reference: GrassoCSGenetic mechanisms of immune evasion in colorectal cancerCancer Discov.201887307491:CAS:528:DC%2BC1cXhtVKjs7nF29510987598468710.1158/2159-8290.CD-17-1327 – reference: CasbonAJInvasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophilsProc. Natl. Acad. Sci. USA2015112E566E5751:CAS:528:DC%2BC2MXhsVeiu70%3D2562450010.1073/pnas.14249271124330753 – reference: JainRKAntiangiogenesis strategies revisited: from starving tumors to alleviating hypoxiaCancer Cell2014266056221:CAS:528:DC%2BC2cXhvFSmt73F25517747426983010.1016/j.ccell.2014.10.006 – reference: HugoWGenomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanomaCell201616535441:CAS:528:DC%2BC28XksVKrsbw%3D26997480480843710.1016/j.cell.2016.02.065 – reference: ChenPLAnalysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockadeCancer Discov.2016682783727301722508298410.1158/2159-8290.CD-15-15451:CAS:528:DC%2BC28Xht12mtbbP – reference: PaulosCMMicrobial translocation augments the function of adoptively transferred self/tumor-specific CD8+T cells via TLR4 signalingJ. Clin. Invest.2007117219722041:CAS:528:DC%2BD2sXoslOns78%3D17657310192450010.1172/JCI32205 – reference: ChaeYKMutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinomaOncotarget201897949796029487705 – reference: RuffiniEClinical significance of tumor-infiltrating lymphocytes in lung neoplasmsAnn. Thorac. Surg.2009873653711916173910.1016/j.athoracsur.2008.10.067 – reference: KarimiKInmanMDBienenstockJForsythePLactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in miceAm. J. Respir. Crit. Care. Med.20091791861931:CAS:528:DC%2BD1MXisFeqsL0%3D1902900310.1164/rccm.200806-951OC – reference: HerbstRSPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature20145155635671:CAS:528:DC%2BC2cXitFanurbM25428504483619310.1038/nature14011 – reference: Petitprez F., et al. PD-L1 expression and CD8+T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer. Eur. Urol. Focus (2017). – reference: ParkMHLeeJSYoonJHHigh expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+T cells, natural killer cells, and dendritic cells in breast carcinomaJ. Surg. Oncol.20121063863921:CAS:528:DC%2BC38XhtFOqtrjM2242219510.1002/jso.23095 – reference: ApoloABAvelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib studyJ. Clin. Oncol.201735211721241:CAS:528:DC%2BC1cXhvFKnsLjE28375787549305110.1200/JCO.2016.71.6795 – reference: SeoANTumour-infiltrating CD8+lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancerBr. J. Cancer2013109270527131:CAS:528:DC%2BC3sXhs1ClsL3M24129232383321910.1038/bjc.2013.634 – reference: BechtEImmune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapyClin. Cancer Res.201622405740661:CAS:528:DC%2BC28XhtlKrsbjL2699414610.1158/1078-0432.CCR-15-2879 – reference: FridmanWHZitvogelLSautès-FridmanCKroemerGThe immune contexture in cancer prognosis and treatmentNat. Rev. Clin. Oncol.2017147177341:CAS:528:DC%2BC2sXht1akt7bM2874161810.1038/nrclinonc.2017.101 – reference: LawrenceMSMutational heterogeneity in cancer and the search for new cancer-associated genesNature20134992142181:CAS:528:DC%2BC3sXpsFSgsbo%3D23770567391950910.1038/nature12213 – reference: HerbstRSPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet Lond. Engl.2016387154015501:CAS:528:DC%2BC2MXitVGrtLzI10.1016/S0140-6736(15)01281-7 – reference: GiraldoNAThe immune contexture of primary and metastatic human tumoursCurr. Opin. Immunol.2014278151:CAS:528:DC%2BC2cXmtVamur8%3D2448718510.1016/j.coi.2014.01.001 – reference: MorvanMGLanierLLNK cells and cancer: you can teach innate cells new tricksNat. Rev. Cancer2016167191:CAS:528:DC%2BC2MXitVOjsbnE2669493510.1038/nrc.2015.5 – reference: GulleyJLAvelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trialLancet Oncol.2017185996101:CAS:528:DC%2BC2sXlsFais7k%3D28373005552271910.1016/S1470-2045(17)30240-1 – reference: VétizouMAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiotaScience20153501079108426541610472165910.1126/science.aad13291:CAS:528:DC%2BC2MXhvFamtL3J – reference: BechtEImmune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancersAdv. Immunol.2016130951901:CAS:528:DC%2BC1MXotVGqsLs%3D2692300110.1016/bs.ai.2015.12.002 – reference: ThomasNETumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma studyJ. Clin. Oncol.2013314252425924127443382101410.1200/JCO.2013.51.3002 – reference: FurusawaYCommensal microbe-derived butyrate induces the differentiation of colonic regulatory T cellsNature20135044464501:CAS:528:DC%2BC3sXhvFOltr3F10.1038/nature1272124226770 – reference: SmithPMThe microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasisScience20133415695731:CAS:528:DC%2BC3sXhtFyjsr3P10.1126/science.124116523828891 – reference: Dieu-NosjeanMCTertiary lymphoid structures, drivers of the anti-tumor responses in human cancersImmunol. Rev.20162712602751:CAS:528:DC%2BC28XmtVOjtL4%3D2708892010.1111/imr.12405 – reference: UramJNPD-1 blockade in tumors with mismatch repair deficiencyJ. Clin. Oncol.20153318_supplLBA10010.1200/jco.2015.33.18_suppl.lba100 – reference: SprangerSBaoRGajewskiTFMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunityNature20155232312351:CAS:528:DC%2BC2MXhtFaitrrL10.1038/nature1440425970248 – reference: McDermottDFAtezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase ia studyJ. Clin. Oncol.2016348338421:CAS:528:DC%2BC2sXhslOhtQ%3D%3D10.1200/JCO.2015.63.742126755520 – reference: ScottDWGene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphomaJ. Clin. Onco.20133169270010.1200/JCO.2012.43.4589 – reference: WeberJSNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialLancet Oncol.2015163753841:CAS:528:DC%2BC2MXkvVWgsLk%3D2579541010.1016/S1470-2045(15)70076-8 – reference: Balar A. V., et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet389, 67–76 (2017). – reference: BuckanovichRJEndothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapyNat. Med.20081428361:CAS:528:DC%2BD1cXisVWjtw%3D%3D1815714210.1038/nm1699 – reference: SilzleTTumor-associated fibroblasts recruit blood monocytes into tumor tissueEur. J. Immunol.200333131113201:CAS:528:DC%2BD3sXjvFyjs74%3D1273105610.1002/eji.200323057 – reference: RizviNAActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialLancet Oncol.2015162572651:CAS:528:DC%2BC2MXjtFShs7s%3D25704439572622810.1016/S1470-2045(15)70054-9 – reference: TopalianSLSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN. Engl. J. Med.2012366244324541:CAS:528:DC%2BC38XhtV2rs7fN22658127354453910.1056/NEJMoa1200690 – volume: 499 start-page: 214 year: 2013 ident: 327_CR144 publication-title: Nature doi: 10.1038/nature12213 – volume: 350 start-page: 1079 year: 2015 ident: 327_CR70 publication-title: Science doi: 10.1126/science.aad1329 – volume: 169 start-page: 570 year: 2017 ident: 327_CR51 publication-title: Cell doi: 10.1016/j.cell.2017.04.004 – volume: 157 start-page: 121 year: 2014 ident: 327_CR58 publication-title: Cell doi: 10.1016/j.cell.2014.03.011 – volume: 61 start-page: 5132 year: 2001 ident: 327_CR92 publication-title: Cancer Res. – volume: 17 start-page: 209 year: 2017 ident: 327_CR16 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.154 – volume: 21 start-page: 836 year: 2012 ident: 327_CR26 publication-title: Cancer Cell doi: 10.1016/j.ccr.2012.04.024 – volume: 16 start-page: 275 year: 2016 ident: 327_CR115 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.36 – volume: 9 start-page: 7949 year: 2018 ident: 327_CR31 publication-title: Oncotarget doi: 10.18632/oncotarget.23742 – volume: 109 start-page: 1676 year: 2013 ident: 327_CR97 publication-title: Br. J. Cancer doi: 10.1038/bjc.2013.493 – volume: 387 start-page: 1540 year: 2016 ident: 327_CR128 publication-title: Lancet Lond. Engl. doi: 10.1016/S0140-6736(15)01281-7 – volume: 44 start-page: 698 year: 2016 ident: 327_CR20 publication-title: Immunity doi: 10.1016/j.immuni.2016.02.025 – volume: 16 start-page: 375 year: 2015 ident: 327_CR119 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(15)70076-8 – volume: 145 start-page: 1121 year: 2013 ident: 327_CR49 publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.07.025 – volume: 357 start-page: 409 year: 2017 ident: 327_CR147 publication-title: Science doi: 10.1126/science.aan6733 – volume: 212 start-page: 1345 year: 2015 ident: 327_CR50 publication-title: J. Exp. Med. doi: 10.1084/jem.20151159 – volume: 407 start-page: 249 year: 2000 ident: 327_CR33 publication-title: Nature doi: 10.1038/35025220 – volume: 77 start-page: 1303 year: 1996 ident: 327_CR83 publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5 – volume: 30 start-page: 2678 year: 2012 ident: 327_CR84 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.37.8539 – volume: 515 start-page: 558 year: 2014 ident: 327_CR135 publication-title: Nature doi: 10.1038/nature13904 – volume: 373 start-page: 1270 year: 2015 ident: 327_CR118 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1504030 – volume: 34 start-page: 3500 year: 2016 ident: 327_CR90 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.34.15_suppl.3500 – volume: 6 start-page: 827 year: 2016 ident: 327_CR150 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-1545 – ident: 327_CR91 – volume: 14 start-page: 717 year: 2017 ident: 327_CR76 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2017.101 – volume: 515 start-page: 563 year: 2014 ident: 327_CR117 publication-title: Nature doi: 10.1038/nature14011 – volume: 373 start-page: 123 year: 2015 ident: 327_CR125 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1504627 – volume: 504 start-page: 446 year: 2013 ident: 327_CR65 publication-title: Nature doi: 10.1038/nature12721 – volume: 71 start-page: 6391 year: 2011 ident: 327_CR5 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-11-0952 – volume: 109 start-page: 2705 year: 2013 ident: 327_CR98 publication-title: Br. J. Cancer doi: 10.1038/bjc.2013.634 – volume: 16 start-page: 7 year: 2016 ident: 327_CR7 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2015.5 – volume: 34 start-page: 2980 year: 2016 ident: 327_CR123 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.66.9929 – ident: 327_CR79 – volume: 504 start-page: 451 year: 2013 ident: 327_CR64 publication-title: Nature doi: 10.1038/nature12726 – volume: 179 start-page: 186 year: 2009 ident: 327_CR60 publication-title: Am. J. Respir. Crit. Care. Med. doi: 10.1164/rccm.200806-951OC – volume: 359 start-page: 97 year: 2018 ident: 327_CR73 publication-title: Science doi: 10.1126/science.aan4236 – volume: 372 start-page: 320 year: 2015 ident: 327_CR120 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1412082 – volume: 8 start-page: 618 year: 2008 ident: 327_CR11 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc2444 – volume: 22 start-page: 4057 year: 2016 ident: 327_CR22 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-2879 – volume: 174 start-page: 4670 year: 2005 ident: 327_CR52 publication-title: J. Immunol. doi: 10.4049/jimmunol.174.8.4670 – volume: 21 start-page: 3969 year: 2015 ident: 327_CR153 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-0244 – volume: 23 start-page: 4416 year: 2017 ident: 327_CR78 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-2848 – volume: 135 start-page: 1228 year: 2008 ident: 327_CR46 publication-title: Gastroenterology doi: 10.1053/j.gastro.2008.07.016 – volume: 130 start-page: 95 year: 2016 ident: 327_CR75 publication-title: Adv. Immunol. doi: 10.1016/bs.ai.2015.12.002 – volume: 113 start-page: 1387 year: 2008 ident: 327_CR105 publication-title: Cancer doi: 10.1002/cncr.23712 – volume: 14 start-page: 28 year: 2008 ident: 327_CR36 publication-title: Nat. Med. doi: 10.1038/nm1699 – volume: 189 start-page: 832 year: 2014 ident: 327_CR43 publication-title: Am. J. Respir. Crit. Care. Med. doi: 10.1164/rccm.201309-1611OC – volume: 106 start-page: 386 year: 2012 ident: 327_CR95 publication-title: J. Surg. Oncol. doi: 10.1002/jso.23095 – volume: 453 start-page: 410 year: 2008 ident: 327_CR40 publication-title: Nature doi: 10.1038/nature06868 – volume: 26 start-page: 605 year: 2014 ident: 327_CR35 publication-title: Cancer Cell doi: 10.1016/j.ccell.2014.10.006 – volume: 35 start-page: 571 year: 2014 ident: 327_CR42 publication-title: Trends Immunol. doi: 10.1016/j.it.2014.09.006 – volume: 5 start-page: 43 year: 2015 ident: 327_CR19 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-14-0863 – volume: 387 start-page: 1837 year: 2016 ident: 327_CR130 publication-title: Lancet doi: 10.1016/S0140-6736(16)00587-0 – volume: 16 start-page: 257 year: 2015 ident: 327_CR127 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(15)70054-9 – volume: 6 year: 2015 ident: 327_CR41 publication-title: Nat. Commun. doi: 10.1038/ncomms8114 – volume: 366 start-page: 2443 year: 2012 ident: 327_CR116 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1200690 – volume: 18 start-page: 599 year: 2017 ident: 327_CR131 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30240-1 – volume: 121 start-page: 3846 year: 2011 ident: 327_CR37 publication-title: J. Clin. Invest. doi: 10.1172/JCI44952 – volume: 113 start-page: E7759 year: 2016 ident: 327_CR32 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1609376113 – volume: 339 start-page: 1546 year: 2013 ident: 327_CR14 publication-title: Science doi: 10.1126/science.1235122 – volume: 69 start-page: 3077 year: 2009 ident: 327_CR39 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-2281 – volume: 178 start-page: 5552 year: 2007 ident: 327_CR45 publication-title: J. Immunol. doi: 10.4049/jimmunol.178.9.5552 – volume: 535 start-page: 75 year: 2016 ident: 327_CR56 publication-title: Nature doi: 10.1038/nature18848 – volume: 21 start-page: 504 year: 2012 ident: 327_CR66 publication-title: Cancer Cell doi: 10.1016/j.ccr.2012.02.007 – ident: 327_CR1 – volume: 500 start-page: 415 year: 2013 ident: 327_CR155 publication-title: Nature doi: 10.1038/nature12477 – volume: 18 start-page: 195 issue: 3 year: 2018 ident: 327_CR34 publication-title: Nature Reviews Immunology doi: 10.1038/nri.2017.145 – volume: 351 start-page: 1463 year: 2016 ident: 327_CR148 publication-title: Science doi: 10.1126/science.aaf1490 – volume: 31 start-page: 692 year: 2013 ident: 327_CR81 publication-title: J. Clin. Onco. doi: 10.1200/JCO.2012.43.4589 – volume: 94 start-page: 275 year: 2006 ident: 327_CR104 publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6602934 – volume: 318 start-page: 1647 year: 2017 ident: 327_CR114 publication-title: JAMA doi: 10.1001/jama.2017.14155 – ident: 327_CR141 doi: 10.1200/JCO.2016.68.1478 – volume: 372 start-page: 2509 year: 2015 ident: 327_CR152 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1500596 – volume: 4 start-page: 11 year: 2004 ident: 327_CR3 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc1252 – volume: 33 start-page: LBA100 issue: 18_suppl year: 2015 ident: 327_CR146 publication-title: J. Clin. Oncol. doi: 10.1200/jco.2015.33.18_suppl.lba100 – volume: 523 start-page: 231 year: 2015 ident: 327_CR21 publication-title: Nature doi: 10.1038/nature14404 – volume: 31 start-page: 214 issue: 2 year: 2017 ident: 327_CR89 publication-title: Modern Pathology doi: 10.1038/modpathol.2017.156 – volume: 67 start-page: 727 year: 2017 ident: 327_CR24 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2017.05.014 – volume: 142 start-page: 355 year: 2013 ident: 327_CR96 publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-013-2752-2 – volume: 18 start-page: 589 year: 2004 ident: 327_CR80 publication-title: Leukemia doi: 10.1038/sj.leu.2403240 – volume: 17 year: 2016 ident: 327_CR156 publication-title: Genome Biol. doi: 10.1186/s13059-016-1070-5 – volume: 348 start-page: 69 year: 2015 ident: 327_CR143 publication-title: Science doi: 10.1126/science.aaa4971 – volume: 467 start-page: 127 year: 2015 ident: 327_CR15 publication-title: Virchows Arch. Int J. Pathol. doi: 10.1007/s00428-015-1787-7 – volume: 81 start-page: 1893 year: 1989 ident: 327_CR82 publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/81.24.1893 – volume: 33 start-page: 1430 year: 2015 ident: 327_CR139 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.59.0703 – volume: 5 start-page: 1062 year: 2017 ident: 327_CR38 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-17-0190 – volume: 128 start-page: 703 year: 2011 ident: 327_CR101 publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-010-1154-y – volume: 123 start-page: 2873 year: 2013 ident: 327_CR100 publication-title: J. Clin. Invest. doi: 10.1172/JCI67428 – volume: 47 start-page: 1083 year: 2017 ident: 327_CR30 publication-title: Immunity doi: 10.1016/j.immuni.2017.11.016 – volume: 33 start-page: 2004 year: 2015 ident: 327_CR126 publication-title: J. Clin. Oncol. J. Am. Soc. Clin. Oncol. doi: 10.1200/JCO.2014.58.3708 – volume: 34 start-page: 833 year: 2016 ident: 327_CR140 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.63.7421 – volume: 8 start-page: 8633 year: 2016 ident: 327_CR48 publication-title: Oncotarget doi: 10.18632/oncotarget.14374 – volume: 5 start-page: 193ra91 year: 2013 ident: 327_CR59 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.3006438 – volume: 373 start-page: 1627 year: 2015 ident: 327_CR124 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1507643 – volume: 117 start-page: 2197 year: 2007 ident: 327_CR68 publication-title: J. Clin. Invest. doi: 10.1172/JCI32205 – volume: 515 start-page: 568 year: 2014 ident: 327_CR151 publication-title: Nature doi: 10.1038/nature13954 – volume: 341 start-page: 569 year: 2013 ident: 327_CR63 publication-title: Science doi: 10.1126/science.1241165 – volume: 14 start-page: 399 year: 2017 ident: 327_CR13 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/nrclinonc.2016.217 – volume: 72 start-page: 1070 year: 2012 ident: 327_CR87 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-11-3218 – volume: 87 start-page: 365 year: 2009 ident: 327_CR106 publication-title: Ann. Thorac. Surg. doi: 10.1016/j.athoracsur.2008.10.067 – volume: 342 start-page: 967 year: 2013 ident: 327_CR69 publication-title: Science doi: 10.1126/science.1240527 – volume: 23 start-page: 8959 year: 2005 ident: 327_CR111 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2005.01.4910 – volume: 478 start-page: 250 year: 2011 ident: 327_CR61 publication-title: Nature doi: 10.1038/nature10434 – volume: 61 start-page: 1849 year: 2012 ident: 327_CR108 publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-012-1231-7 – volume: 27 start-page: 8 year: 2014 ident: 327_CR2 publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2014.01.001 – volume: 165 start-page: 35 year: 2016 ident: 327_CR149 publication-title: Cell doi: 10.1016/j.cell.2016.02.065 – volume: 51 start-page: 97 year: 2018 ident: 327_CR154 publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2018.03.005 – ident: 327_CR133 doi: 10.1016/S0140-6736(16)32455-2 – volume: 19 start-page: S71 year: 2006 ident: 327_CR86 publication-title: Mod. Pathol. doi: 10.1038/modpathol.3800517 – volume: 8 start-page: 730 year: 2018 ident: 327_CR23 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-17-1327 – volume: 162 start-page: 1229 year: 2015 ident: 327_CR54 publication-title: Cell doi: 10.1016/j.cell.2015.08.016 – volume: 359 start-page: 91 year: 2018 ident: 327_CR71 publication-title: Science doi: 10.1126/science.aan3706 – volume: 3 start-page: e172411 year: 2017 ident: 327_CR137 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2017.2411 – volume: 333 start-page: 222 year: 2013 ident: 327_CR112 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2013.01.036 – volume: 271 start-page: 260 year: 2016 ident: 327_CR4 publication-title: Immunol. Rev. doi: 10.1111/imr.12405 – volume: 17 start-page: 717 year: 2016 ident: 327_CR142 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)00175-3 – volume: 475 start-page: 222 year: 2011 ident: 327_CR9 publication-title: Nature doi: 10.1038/nature10138 – volume: 359 start-page: 104 year: 2018 ident: 327_CR72 publication-title: Science doi: 10.1126/science.aao3290 – volume: 167 start-page: 207 year: 2011 ident: 327_CR107 publication-title: J. Surg. Res. doi: 10.1016/j.jss.2009.08.029 – volume: 456 start-page: 507 year: 2008 ident: 327_CR57 publication-title: Nature doi: 10.1038/nature07450 – ident: 327_CR88 – volume: 17 start-page: 330 year: 2015 ident: 327_CR113 publication-title: Clin. Transl. Oncol. doi: 10.1007/s12094-014-1235-1 – volume: 9 start-page: 1269 year: 2003 ident: 327_CR55 publication-title: Nat. Med. doi: 10.1038/nm934 – volume: 1 start-page: 54 year: 2011 ident: 327_CR102 publication-title: Cancer Discov. doi: 10.1158/2159-8274.CD-10-0028 – volume: 75 start-page: 275 issue: 2 year: 2014 ident: 327_CR53 publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-14-1491 – volume: 4 start-page: e1049804 year: 2015 ident: 327_CR93 publication-title: Oncoimmunology doi: 10.1080/2162402X.2015.1049804 – volume: 47 start-page: 261 year: 2013 ident: 327_CR121 publication-title: J. Clin. Orthod. – volume: 17 start-page: 1590 year: 2016 ident: 327_CR132 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30496-X – volume: 34 start-page: 3119 year: 2016 ident: 327_CR136 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.67.9761 – volume: 112 start-page: E566 year: 2015 ident: 327_CR28 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1424927112 – volume: 16 start-page: 431 year: 2016 ident: 327_CR29 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.52 – volume: 12 start-page: 298 year: 2012 ident: 327_CR74 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3245 – volume: 30 start-page: 531 year: 2012 ident: 327_CR12 publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.immunol.25.022106.141623 – volume: 31 start-page: 4252 year: 2013 ident: 327_CR85 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2013.51.3002 – volume: 74 start-page: 705 year: 2014 ident: 327_CR6 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-1342 – volume: 348 start-page: 124 year: 2015 ident: 327_CR145 publication-title: Science doi: 10.1126/science.aaa1348 – volume: 342 start-page: 971 year: 2013 ident: 327_CR67 publication-title: Science doi: 10.1126/science.1240537 – volume: 15 start-page: 857 year: 2016 ident: 327_CR17 publication-title: Cell Rep. doi: 10.1016/j.celrep.2016.03.075 – volume: 19 start-page: 1264 year: 2013 ident: 327_CR10 publication-title: Nat. Med. doi: 10.1038/nm.3337 – volume: 171 start-page: 1301 year: 2017 ident: 327_CR25 publication-title: Cell doi: 10.1016/j.cell.2017.11.013 – volume: 9 start-page: e95475 year: 2014 ident: 327_CR99 publication-title: PLoS. ONE doi: 10.1371/journal.pone.0095475 – volume: 107 start-page: 20009 year: 2010 ident: 327_CR44 publication-title: Proc. Natl. Acad. Sci. doi: 10.1073/pnas.1013805107 – volume: 2 year: 2011 ident: 327_CR8 publication-title: Nat. Commun. doi: 10.1038/ncomms1239 – volume: 377 start-page: 1345 year: 2017 ident: 327_CR122 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1709684 – volume: 155 start-page: 858 issue: 4 year: 2013 ident: 327_CR18 publication-title: Cell doi: 10.1016/j.cell.2013.10.015 – volume: 65 start-page: 159 year: 2012 ident: 327_CR103 publication-title: J. Clin. Pathol. doi: 10.1136/jclinpath-2011-200355 – volume: 500 start-page: 232 year: 2013 ident: 327_CR62 publication-title: Nature doi: 10.1038/nature12331 – volume: 35 start-page: 2117 year: 2017 ident: 327_CR138 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.71.6795 – volume: 387 start-page: 1909 year: 2016 ident: 327_CR134 publication-title: Lancet doi: 10.1016/S0140-6736(16)00561-4 – volume: 111 start-page: 4221 year: 2014 ident: 327_CR27 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1320753111 – volume: 33 start-page: 1311 year: 2003 ident: 327_CR47 publication-title: Eur. J. Immunol. doi: 10.1002/eji.200323057 – volume: 21 start-page: 3031 year: 2015 ident: 327_CR77 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-2926 – volume: 37 start-page: 1560 year: 2015 ident: 327_CR109 publication-title: Cell Physiol. Biochem. doi: 10.1159/000438523 – volume: 33 start-page: 118 year: 2009 ident: 327_CR110 publication-title: Eur. Respir. J. doi: 10.1183/09031936.00065708 – volume: 372 start-page: 2018 year: 2015 ident: 327_CR129 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1501824 – volume: 39 start-page: 7 year: 2016 ident: 327_CR94 publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2015.11.009 |
| SSID | ssj0009087 |
| Score | 2.6985264 |
| SecondaryResourceType | review_article |
| Snippet | The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial... |
| SourceID | pubmedcentral hal proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 45 |
| SubjectTerms | 631/67/580/1884 692/4028/67/1059/2325 692/4028/67/327 692/53/2422 Biomedical and Life Sciences Biomedicine Cancer Cancer Research Cancer-Associated Fibroblasts - immunology Cancer-Associated Fibroblasts - pathology Cell Proliferation - genetics Colorectal cancer Colorectal carcinoma Cytotoxicity Drug Resistance Endothelial cells Endothelial Cells - immunology Endothelial Cells - pathology Epidemiology Fibroblasts Humans Immunotherapy Kidney cancer Life Sciences Lymphocytes T Melanoma Metastases Molecular Medicine Neoplasm Invasiveness - genetics Neoplasm Invasiveness - pathology Neoplasms - immunology Neoplasms - pathology Oncology Phenotypes Renal cell carcinoma Review Review Article Solid tumors T-Lymphocytes, Cytotoxic - immunology T-Lymphocytes, Cytotoxic - pathology Tumor Microenvironment - immunology Tumors |
| Title | The clinical role of the TME in solid cancer |
| URI | https://link.springer.com/article/10.1038/s41416-018-0327-z https://www.ncbi.nlm.nih.gov/pubmed/30413828 https://www.proquest.com/docview/2165066488 https://www.proquest.com/docview/2132229472 https://hal.sorbonne-universite.fr/hal-01985551 https://pubmed.ncbi.nlm.nih.gov/PMC6325164 |
| Volume | 120 |
| WOSCitedRecordID | wos000455095200007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: M7P dateStart: 20190101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 7X7 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 7RV dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: BENPR dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Public Health Database customDbUrl: eissn: 1532-1827 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0009087 issn: 0007-0920 databaseCode: 8C1 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB51oap6KX03LV2lVU9tI-zEjp0TArSIA6xWiKK9RbbjiJWqLN1dOPDrO5PXakHl0osPsS3bmbH92TP-BuAbs6WxskgjXjYhzExkEisjXxpZCuUyUTtjXp6q8VhPp9mkvXBbtm6V3ZpYL9TF3NEd-V7MEUukKerb_vWfiKJGkXW1DaExgG1iSYhr173JmnSX6YYzk67jsri3aiZ6byk4QhE8SNMDs1hFdxv70uCKvCIfQs6HnpP3zKf1rnS887_jeQkvWjwaHjQK9Aqe-Oo1PDtrLe5v4CfqUdg9nwzJFzGclyGixvDibBTOqhB1d1aEjpRn8RZ-HY8ujk6iNsJC5KRiq6iwxqSOJdYLXvJEMe-NVEVacENB0pWX3mfKaaWl0bLAs1lcZrHWKHhERlYn72Crmlf-A2A7BbOJj4XPnHClyRjt_1bYkhPlWhwA6_5v7lr6cYqC8TuvzeCJzhuR5CiSnESS3wXwva9y3XBvPFb4KwqtL0es2ScHpzl9QxSrJSLDWx7AbieMvJ2ry3wtiQC-9Nk4y8h0Yio_v6EyZJHKhMJxvG9UoG8qYYKIHLG22lCOjb5s5lSzq5rJO00QXqYigB-dGq279c-Rfnx8EJ_gOYK6rLkm2oWt1eLGf4an7nY1Wy6GMFDnl5ROVZ1qTPURH8L24Wg8OR_WE-gv-U8ZeQ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB61BQGX8obQAgbBpRA1Dye2DwhVpdVW3V1xWFBvxnEcdSWULbvbIvqj-hs7k9dqqeitB66xHduZb5zPnvEMwLsgK0yW5KkfFnUKM-ObOEt8V5ik4MIqXjljfu-L4VAeHamvK3DR3oUht8p2TawW6nxi6Yx8OwqRS6Qp4u3zyS-fskaRdbVNoVHD4tD9-Y1bttmngy8o3_dRtL832u35TVYB3yYimPt5ZkxqgzhzPCzCWATOmUTkaR4aSgwuXOKcElYKmRiZ5LgfiQoVSYmTRTaQyRjfuwq3KJIdaZTcXbiUqEDWMTrp-E9FnRU1ltszHiL1wY07XWiLhH--9B9cPSYvzKsU96qn5l_m2uovuH__f_t-D2C94dtsp1aQh7DiykdwZ9B4FDyGj6gnrL0eysjXkk0KhqyYjQZ7bFwy1M1xziwpx_QJfLuRsT6FtXJSuueA_eRBFruIO2W5LYwKiN9kPCtCCikXeRC08tS2Ca9OWT5-6srMH0tdQ0AjBDRBQJ97sNU1Oalji1xX-S2CpKtHUcF7O31Nz5ClywSZ71nowWYrfN2sRTO9kLwHb7piXEXINGRKNzmlOmRxU1zgPJ7VkOu6igNOgSqxtVgC49JYlkvK8XEVqTyNkT6n3IMPLWwXw_rnTF9cP4nXcLc3GvR1_2B4uAH3kMCq-khsE9bm01P3Em7bs_l4Nn1VKSeDHzeN5ktfN3F7 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB61Kaq48H4sFDAILsAq-_CuvQeECk3UqmkUoVL1ZrxeW42ENiVJi-hP49cxk31EoaK3Hriu7bVn_Y33s2c8A_A6yJ3OkyL1Q1elMNO-jvPEt04njguT8YUz5tFADIfy-DgbrcHv5i4MuVU2a-JioS4mhs7Iu1GIXCJNEW9dV7tFjHb6H09_-JRBiiytTTqNCiL79tdP3L7NPuzt4Fy_iaJ-7_Dzrl9nGPBNIoK5X-RapyaIc8tDF8YisFYnokiLUFOScGETazNhpJCJlkmBe5PIZZGUKDgyg1zG-N512BBIMngHNj71hqMvy5C_gawidtJhYBa1NtVYdmc8RCKE23i63hYJ_2Llr7h-Qj6ZlwnvZb_Nv4y3i39i__b__DXvwK2aibPtSnXuwpot78HmQe1rcB_eowax5uIoIy9MNnEM-TI7POixcclQa8cFM6Q20wfw9VrG-hA65aS0jwH7KYI8thG3meHG6Swg5pPz3IUUbC7yIGjmVpk68Drl__iuFg4AsVQVHBTCQREc1IUHb9smp1XUkasqv0LAtPUoXvju9kDRM-TvMkFOfB56sNUAQdWr1EwtUeDBy7YY1xcyGunSTs6oDtniMi5QjkcV_Nqu4oBTCEtsLVaAuTKW1ZJyfLKIYZ7GSKxT7sG7BsLLYf1T0idXC_ECNhHEarA33H8KN5HZZtVZ2RZ05tMz-wxumPP5eDZ9Xmsqg2_XDec_62972Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+clinical+role+of+the+TME+in+solid+cancer&rft.jtitle=British+journal+of+cancer&rft.au=Giraldo%2C+Nicolas+A&rft.au=Sanchez-Salas%2C+Rafael&rft.au=Peske%2C+J+David&rft.au=Vano%2C+Yann+A&rft.date=2019-01-01&rft.pub=Cancer+Research+UK&rft.issn=0007-0920&rft.eissn=1532-1827&rft.volume=120&rft.issue=1&rft.spage=45&rft.epage=53&rft_id=info:doi/10.1038%2Fs41416-018-0327-z&rft_id=info%3Apmid%2F30413828&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=oai%3AHAL%3Ahal-01985551v1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon |